

RECOMBINANT VACCINE AGAINST JAPANESE ENCEPHALITIS VIRUS (JEV) INFECTION AND A METHOD THEREOF

Field of the invention

5 The present invention relates to a method of preparing a novel recombinant adenovirus (RAdEs) vaccine to protect against Japanese encephalitis virus (JEV) infection. Also, it relates to a method of immunization and to the vaccine *per se*.

Background and prior art references of the invention

Japanese encephalitis virus (JEV) is a member of the *flaviviridae* family of animal
10 viruses that consists of several viruses of immense medical significance such as those causing dengue and yellow fever. JEV, transmitted to human beings by mosquitoes, is responsible for an acute infection of the central nervous system resulting in encephalitis. The virus is active over a vast geographic area covering India, China, Japan and virtually all of the South-East Asia. Approximately 3 billion people live in
15 JEV endemic area and up to 50,000 cases of JEV infection are reported every year, of which, about 10,000 cases result in fatality and a high proportion of survivors end up having serious neurological and psychiatric sequel (45). A mouse brain-grown, formalin-inactivated JEV vaccine is available internationally. However, this vaccine has limitations in terms of its high cost of production, lack of long-term immunity and
20 risk of allergic reaction due to the presence of the murine encephalogenic basic proteins or gelatin stabilizer (1, 33, 38, 39). There is, thus, an urgent need to develop an improved vaccine against JEV and several potential vaccines are currently being investigated in various laboratories (16).

JEV contains a single-stranded, plus-sense RNA genome of ~11 Kb. It consists of a
25 single open reading frame that codes for a large polyprotein of 3432 amino acids which is co- and post-translationally cleaved into three structural (capsid, C; pre-membrane, prM; and envelope, E) and seven non-structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5) (5, 44). In flaviviruses, E protein is involved in a number of important functions related to virus infection such as receptor binding and membrane
30 fusion (26). Antibodies to the E protein were shown to neutralize virus activity *in vitro* as well as *in vivo* since passive administration of monoclonal antibodies to the E protein protected mice with JEV infection (17). Furthermore, sub-viral particles consisting of only the prM and the E proteins were highly effective in generating protective immune response in mice against JEV (18, 25). Chen *et al.* (7) examined the potential of

various JEV structural and non-structural proteins for vaccine development. They concluded that the E protein was the single most important protein capable of inducing protective immunity against JEV. Accordingly, several plasmid vectors have been described synthesizing different forms of JEV E protein with or without prM protein and these provided protection of varying degree in mice against Japanese encephalitis (2, 6, 15, 20).

In recent years, adenoviruses have shown great promise as vectors for recombinant vaccine development (3, 4, 8, 13, 35, 41, 42, 49). Besides being safe, these viruses have been shown to induce effective humoral and cellular immune responses in experimental animals when delivered orally, intra-muscular (IM), intra-peritoneal or intra-nasal (3, 21, 24, 40, 41, 50). In the present invention, we constructed RAdEa expressing the prM and the full length JEV E protein since it is known to induce neutralizing immune response. However, adenovirus recombinant (RAdEa) synthesizing the full-length protein (Ea) did not grow well. Besides it induced poor immune response and very little JEV neutralizing antibodies. The full-length E protein is membrane anchored and removing the anchor signal from it is likely to make it soluble and perhaps more immunogenic.

On this premise, we truncated the Ea protein to remove 102-amino acid hydrophobic sequence from the C-terminus of the protein to generate a 398-amino acid Es protein. Recombinant adenovirus RAdEs synthesizing JEV prM and Es was found to grow very well in cultured cells and synthesize JEV E protein that was secreted into the medium. So, the removal of 102-amino acid hydrophobic sequence from the C-terminus of the protein played a critical role in smooth culturing of the recombinant. Even the inventors were pleasantly surprised with this effect.

Further, this recombinant adenovirus, synthesizing a novel form of JEV E protein that was secretory as opposed to the anchored protein in the normal course, was highly immunogenic in mice. RAdEs induced high titers of JEV neutralizing antibodies and protected the immunized mice against lethal JEV challenge demonstrating its potential use as a vaccine against JEV infection. The highly immunogenic effect of the recombinant helped achieve the desired results, which were long awaited by the scientific community.

The infection caused by JEV is fatal in nature and absence of long-term immunity had added to the problem. The allergic reactions to the known vaccine had further

compounded the problem. However, administration of the vaccine of instant invention is been found to be absolutely safe and free from adverse effects.

Objects of the invention

The main object of the present invention is to develop a recombinant adenovirus (RAdEs) vaccine against JEV infection.

Another main object of the present invention is to develop an effective and superior method of immunization to Japanese encephalitis virus (JEV) infection.

Yet another object of the present invention is to develop a plasmid pAdEs of SEQ ID No. 1.

Still another object of the present invention is to develop a method of preparing a recombinant adenovirus (RAdEs) vaccine to protect against Japanese encephalitis virus (JEV) infection.

Summary of the invention

The present invention relates to development of a novel recombinant adenovirus (RAdEs) vaccine against Japanese encephalitis virus (JEV) infection.

Detailed description of the invention

Accordingly, the present invention relates to a novel recombinant adenovirus (RAdEs) vaccine against JEV infection; an effective and superior method of immunization to Japanese encephalitis virus (JEV) infection; also, a plasmid pAdEs of SEQ ID No. 1; and lastly, a method of preparing the recombinant adenovirus (RAdEs) vaccine.

In the main embodiment of the present invention, it relates to a method of preparing a recombinant adenovirus (RAdEs) vaccine to protect against Japanese encephalitis virus (JEV) infection, wherein the said vaccine produces secretory envelop protein of JEV, said method comprising steps of:

- digesting plasmid pMEs with restriction enzymes *Kpn* I and *Bam* HI to obtain cDNA encoding JEV proteins prM and Es,
- ligating the cDNA to adenovirus shuttle plasmid pShuttle digested with restriction enzymes *Kpn* I and *Hind* III at the *Kpn* I end,
- filling nucleotides at the free *Bam* HI and *Hind* III ends with T4 DNA polymerase to create blunt ends,
- ligating the blunt ends together to yield shuttle plasmid pSEs with JEV cDNA encoding the proteins prM and Es,

- digesting the shuttle plasmid pSEs with restriction enzymes *I-Ceu I* and *PI-Sce I* to obtain expression cassette containing the JEV cDNA together with the CMV promoter/enhancer and BGH polyadenylation signal,
- 5 • ligating the digested shuttle plasmid with *I-Ceu I* and *PI-Sce I* digested adenovirus plasmid pAdeno-X to generate plasmid pAdEs containing the Es expression cassette,
- digesting the plasmid pAdEs with *Pac I*,
- transfecting the monolayers of HEK 293 cells with digested plasmid
10 pAdEs for about one week, and
- obtaining the recombinant virus RAdEs vaccine.

In another embodiment of the present invention, the transfection is at about 37⁰C temperature.

In yet another embodiment of the present invention, the secretory proteins are under the
15 control of human CMV IE promoter/enhancer.

In another main embodiment of the present invention, the invention relates to a recombinant adenovirus (RAdEs) vaccine.

In yet another embodiment of the present invention, the vaccine produces secretory envelop protein (Es) of JEV.

20 In still another embodiment of the present invention, the vaccine protects against Japanese encephalitis virus (JEV) infection.

In still another embodiment of the present invention, the vaccine is effective by intra-muscular route of administration.

In another main embodiment of the present invention, the invention relates to a plasmid
25 pAdEs of SEQ ID No. 1.

In another main embodiment of the present invention, the invention relates to an effective and superior method of immunizing a subject in need thereof, to Japanese encephalitis virus (JEV) infection, said method comprising the step of administering a pharmaceutically effective amount of recombinant virus RAdEs vaccine optionally
30 along with additive(s) to the subject intra-muscularly.

In yet another embodiment of the present invention, the method shows 100% efficacy.

In still another embodiment of the present invention, the method helps protect subject against Japanese encephalitis.

In still another embodiment of the present invention, the subject is animal.

In still another embodiment of the present invention, the subject is a human being.

In still another embodiment of the present invention, the immunization activates both humoral and cell-mediated immune responses.

5 In still another embodiment of the present invention, the humoral response to the vaccine is antibody IgG1 type.

In still another embodiment of the present invention, the method leads to high amount of IFN-gamma secretion.

10 In still another embodiment of the present invention, the immunization leads to IL-5 secretion at moderate levels.

In still another embodiment of the present invention, increased amounts of RAdEs lead to higher immune response.

In still another embodiment of the present invention, the method is more effective than the commercially available vaccine.

15 Replication-defective recombinant adenoviruses (RAds) were constructed that synthesized the pre-Membrane (prM) and envelope (E) proteins of Japanese encephalitis virus (JEV). Recombinant virus RAdEa synthesized Ea, the membrane-anchored form of the E protein, and RAdEs synthesized Es, the secretory E protein. RAdEa replicated poorly in human embryonic kidney (HEK) 293A cells and 88-folds
20 lower titers of the virus were obtained compared to RAdEs. RAdEa also synthesized lower amounts of E protein in HEK 293A cells as judged by radioimmunoprecipitation and immunofluorescence studies.

Mice were immunized intra-muscular (IM) and orally with RAds. Oral route of virus delivery induced low titers of anti-JEV antibodies that had only little JEV neutralizing
25 activity. IM immunizations with both RAdEa and RAdEs resulted in high titers of anti-JEV antibodies. Interestingly, RAdEa induced very low titers of JEV neutralizing antibodies whereas RAdEs inoculation resulted in high titers of JEV neutralizing antibodies. Splenocytes from mice immunized IM with RAds secreted large amounts of interferon- γ and moderate amounts of interleukin-5. These splenocytes also showed
30 cytotoxic activity against JEV-infected cells. Mice immunized IM with RAdEs showed complete protection against the lethal dose of JEV given intra-cerebral.

Brief description of the accompanying drawings:

Fig. 1 shows Growth of RAdS in HEK 293A cells. Monolayers of HEK 293A cells in 35-mm tissue culture dishes were infected with RAdS at a multiplicity of infection (MOI) of 1 and incubated at 37 °C in 3 ml culture medium. At 6 hr interval the cell monolayers were lysed in the culture medium by three cycles of freeze-thawing. The cell lysate was centrifuged to remove the debris and the supernatant assayed for adenovirus titers on HEK 293A cells. Shown in the figure are virus titers at various time points.

Fig. 2 shows Synthesis of JEV proteins in HEK 293A cells infected with RAdS. HEK 293A cells were infected with JEV or RAdS at a MOI of 1. Cells were labelled 24 hr later by growth in medium containing ³⁵S-methionine and ³⁵S-cystine. After labeling, culture supernatant (CS) and cells were harvested separately. Cells were washed with PBS before the cell lysate (CL) was made. CLs and CSs were used for immunoprecipitation of JEV proteins with mouse anti-JEV serum. The proteins were separated on a 12% SDS-polyacrylamide gel and autoradiographed. Lanes containing proteins precipitated from JEV-, RAdEa- or RAdEs-infected or uninfected cells have been identified. Position of JEV proteins has been indicated at the left. Ea, Es and prM proteins synthesized by RAdS have been indicated. The values on the right are molecular size markers in kDa.

Fig. 3 shows Immunofluorescent staining of virus-infected cells. HEK 293A cells were infected with RAdS or JEV at a MOI of 1. The cells were fixed and permeabilized 24 hr later and stained with mouse anti-JEV serum followed by FITC-conjugated goat anti-mouse-IgG. They were then observed under a microscope using ultra-violet light. Panel A, RAdEa-infected cells; panel B, RAdEs-infected cells; panel C, JEV-infected cells and panel D, uninfected cells.

Fig. 4 shows Antibody response in mice. BALB/c mice were immunized with RAdEa, RAdEs or with the vaccine by IM or oral route of inoculation. The dosages of the immunogens (in PFU for RAdS) and the routes of inoculation have been indicated below the figure. *indicates oral immunization where virus was diluted in 100 mM Sodium bicarbonate buffer (pH 8.9). The primary immunization was followed by booster doses that were given 21 and 36 days later. Mice were bled at day 20, 28 and 44 post-immunization and sera stored at -70 °C. Serial two-fold dilutions of sera (starting at 1:25) were assayed for the end-point anti-JEV antibody titers by ELISA.

Shown above are mean end-point titers of sera obtained from immunized mice as indicated below the figure. The open bars represent titers on day 20, the gray bars represent titers on day 28 and black bars show titers on day 44 post-immunization.

Fig. 5 shows Isotype analysis of anti-JEV antibody produced by immunized mice.

5 BALB/c mice were immunized with RAdEa, RAdEs or with the vaccine by IM or oral route of inoculation. The dosages of the immunogens (in PFU for RAdEs) and the routes of inoculation have been indicated below the figure. The primary immunization was followed by booster doses given 21 and 36 days later. Mice sera obtained on day 44 post-immunization were assayed for the end-point ELISA titers of anti-JEV IgG1 and
10 IgG2a antibodies. Serial two-fold dilutions of sera (starting at 1:25) were assayed for the end-point titers. The ELISA titer was recorded as zero if the 1:25 dilution of sample was negative in ELISA. Shown in the figure are mean end-point titers of sera obtained from immunized mice as indicated below the figure. The open bars represent IgG1 titers and the gray bars represent IgG2a titers. The inverted triangle indicates zero mean
15 titer.

Fig. 6 shows JEV neutralizing antibody response in mice. BALB/c mice were immunized with RAdEa, RAdEs or the vaccine by IM or oral route of inoculation. The dosages of the immunogens and the route of inoculation have been indicated at the top of the figure. The primary immunization was followed by booster doses given 21 and
20 36 days later. *indicates oral immunization where virus was diluted in 100 mM Sodium bicarbonate buffer. Mice were bled on day 44 post-immunization and sera stored at -70°C . Serial two-fold dilutions of sera (starting at 1:10) were assayed for end-point JEV neutralization titers by plaque reduction neutralization assays. Shown in the figure are mean JEV neutralization titers of serum samples from immunized mice.

25 **Fig. 7** shows Cytokine production by splenocytes from immunized mice. BALB/c mice were immunized with RAdEa, RAdEs or the vaccine by IM or oral route of inoculation as indicated at the top of the figure. These mice were given two booster doses as described in the methods. One week after the second booster dose splenocytes from two mice (indicated by gray and black bars) from each immunization group were
30 cultured in presence of JEV. Culture supernatants were collected each day and stored at -70°C . These were then assayed for IFN- γ , IL-4 and IL-5. Shown in the figure are the levels of IFN- γ and IL-5 in splenocyte cultures on various days after incubation with JEV. The days are numbered at the bottom of the panel.

Fig. 8 shows CTL activity in immunized mice. BALB/c mice were immunized with RAdEa or RAdEs by IM route of inoculation. These mice were given two booster doses as described in the methods. One week after the second booster dose splenocytes from two mice (indicated by gray and black bars) from each immunization group were
5 cultured in presence of JEV for the generation of effector cells. Shown in the figure is the CTL activity of splenocytes at various ratios of effector cells to target cells (E : T) which are indicated at the bottom of the panels.

Fig. 9 shows Mice survival after challenge. Groups of 6-8 BALB/c mice were immunized with various dosages of RAdEa and RAdEs through IM or oral route.
10 These mice received two booster doses of the immunogen on day 22 and 36 post-immunization. Mice were challenged on day 44 post-immunization with 100 LD₅₀ (50%-lethal dose) of JEV given intra-cerebrally. Mice were observed for mortality for the next three weeks. Shown above is the percentage of surviving mice at a given time point. Immunogen dose and route of inoculation have been indicated. *indicates oral
15 delivery of RAdEs along with the bicarbonate buffer.

The invention is further elaborated with the help of experimental data, as presented below in the form of examples. However, the examples should not be construed to limit the scope of the invention

Example – 1

JEV and cells: The GP78 strain of JEV was used in these studies (44). The virus was grown in neonatal mouse brain. The brain from infected mice was homogenized as a 10% suspension in Eagle's minimal essential medium (EMEM). The suspension was centrifuged and filtered through 0.22 µm sterile filters. The virus was stored at -70 °C in aliquots. Virus titration was carried out by plaque assay on porcine stable kidney
20 (PS) monolayers as described previously (43). Adenovirus was grown in human embryonic kidney (HEK) 293A cells (Quantum Biotechnologies Inc.) cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum (FCS).
25

Example – 2

Construction of recombinant adenoviruses: Recombinant adenoviruses were constructed using the Adeno-X expression system (BD Biosciences) that utilized a ligation-based strategy for producing recombinant virus. Using this system a mammalian expression cassette containing the cDNA encoding JEV E protein was
30

incorporated into a replication incompetent (E1/ E3) human adenovirus type 5 (Ad5) genome. Two recombinant adenoviruses (RAds) were made; RAdEa, synthesizing JEV prM and the membrane-anchored E protein, and RAdEs, synthesizing prM and the secretory E protein. Plasmids pMEa and pMEs that contained the cDNAs encoding JEV prM and the membrane-anchored (Ea) or secretory E protein (Es), respectively have been described previously (15). Plasmid pMEa was modified by site-directed mutagenesis to contain an *Afl* II restriction site down-stream of the 3'-end of the JEV cDNA past the *Bam* HI site. The JEV cDNA encoding the prM and Ea proteins was excised from the mutated pMEa as a *Kpn* I - *Afl* II fragment and cloned at these sites in the adenovirus shuttle plasmid pShuttle (BD Biosciences) under the control of human cytomegalovirus (CMV) immediate early (IE) promoter/enhancer to yield plasmid pSEa. The shuttle plasmid pSEa contained the bovine growth hormone (BGH) polyadenylation signal downstream of the cloned JEV cDNA. The cDNA encoding prM and Es sequence was obtained by digesting pMEs with *Kpn* I and *Bam* HI. This cDNA fragment was ligated to the adenovirus shuttle plasmid, pShuttle, digested with *Kpn* I and *Hind* III at the *Kpn* I end. The free *Bam* HI and *Hind* III ends were nucleotide filled with T4 DNA polymerase and the blunt ends so created were ligated together to yield plasmid pSEs where JEV cDNA encoding prM and Es was under the control of human CMV IE promoter/enhancer. The shuttle plasmid pSEs contained the BGH polyadenylation signal downstream of the cloned cDNA. The junctions of the shuttle plasmid and the cDNA insert were sequenced to confirm the presence of the cDNA in correct frame. The plasmids pSEa and pSEs were digested with I-*Ceu* I and P1-*Sce* I to obtain the expression cassettes containing the JEV cDNA together with CMV promoter/enhancer and BGH polyadenylation signal. These were then ligated with I-*Ceu* I and P1-*Sce* I digested adenovirus plasmid pAdeno-X (BD Biosciences) to generate plasmids pAdEa and pAdEs containing the Ea and Es expression cassettes, respectively. Monolayers of HEK 293A cells were transfected with *Pac* I digested pAdEa and pAdEs using Effectene (Qiagen) and incubated for a week at 37 °C. By this time, RAd plaques had begun to show. The cell monolayers were harvested in culture supernatant, frozen-thawed thrice and centrifuged to obtain the released crude recombinant virus that was amplified once in HEK 293A cells and subjected to 2 rounds of plaque purification to obtain recombinant viruses RAdEa and RAdEs.

Example – 3

Radioimmunoprecipitation: Synthesis of JEV proteins by RAdEa and RAdEs was studied by infection of HEK 293A cells followed by radiolabelling and immunoprecipitation. Briefly, monolayers of HEK 293A cells were infected with virus at a multiplicity of infection (MOI) of 1 and incubated at 37 °C. After 24 hr, the cell monolayer was radiolabelled by growing in presence of 100 µCi of Easytag™ EXpre³⁵S³⁵S protein labeling mix (NEN) for 4 hr. The culture supernatant was harvested and stored at -70 °C. The monolayers were harvested in 500 µl of radioimmunoprecipitation assay buffer (10 mM Tris-HCl pH 8.0, 140 mM NaCl, 5 mM Iodoacetamide, 0.5% Triton X-100, 1% Sodium dodecyl sulphate (SDS), 1% Sodium deoxycholate, 2 mM Phenylmethylsulfonyl fluoride). Immunoprecipitation was carried out using mouse anti-JEV serum (ATCC) and Protein A Sepharose beads (Amersham). Immunoprecipitated proteins were electrophoresed on a 12% SDS-polyacrylamide gel that was dried before exposing to X-ray film for autoradiography.

Example – 4

Immunofluorescent staining: Monolayers of HEK 293A cells were infected with RAdEa, RAdEs or JEV at a MOI of 1. The cells were fixed the next day with 2% Paraformaldehyde and permeabilized with 0.1% Triton-X 100. These cells were then stained by incubation with mouse anti-JEV serum (ATCC) followed by anti-mouse IgG-FITC conjugate (Dako) and observed under a microscope using ultra-violet light.

Example – 5

Mice immunization and challenge experiments: All immunizations were carried out on 4-5-week-old inbred BALB/c mice. Each immunization group consisted of 6-8 mice. For IM immunizations, mice were injected in the hind legs with different amounts of RAds diluted in 100 µl phosphate-buffered saline (PBS) using a 30G needle. Another group of mice was immunized with the mouse brain-derived, formalin-inactivated JEV vaccine manufactured by the Central Research Institute, Kasauli (India). Each mouse was given an IM injection of 100 µl of the vaccine that was 1/10th of the recommended adult human dose. For oral immunizations, water was withdrawn from the mice cages for 6-8 hr and then 200-400 µl virus diluted in PBS or 100 mM Sodium bicarbonate buffer (ph 8.9) was administered per oral using a mouse-feeding needle that had a small balloon at the point of the delivery. Two booster doses, given 3 and 5 weeks after the primary immunization, contained the same amount of

immunogen as the primary dose. At 44 days post-immunization, mice were challenged with intra-cerebral inoculation of the lethal dose of JEV. These mice were observed for mortality for the next 3 weeks.

Example – 6

5 **Antibody assays:** Titers of anti-JEV antibodies were assayed using an enzyme-linked immunosorbent assay (ELISA). An ELISA plate was coated with C6/36 cell-grown JEV overnight at 4 °C in 0.2 M Sodium carbonate buffer, pH 9.6 (36). The plate was washed with PBS containing 0.1% Tween-20 (PBS-T) thrice and the wells were blocked with 1% Lactogen in PBS-T at 37 °C for 2 hr. The plate was again washed
10 with PBS-T thrice and incubated with 100 µl diluted mice sera per well at 37 °C for 1 hr. Serial two-fold dilutions of sera were assayed starting at a dilution of 1:25. The plate was then washed thrice with PBS-T and 100-µl anti-mouse antibody conjugated to horse radish peroxidase (HRP) (Dako), diluted 1:2000, was added per well, followed by incubation at 37 °C for 1 hr. The antibody-conjugate was removed by washing the
15 plate thrice with PBS-T. The plate was then incubated in dark with 100 µl per well of the substrate o-Phenylenediamine dihydrochloride (0.5 mg/ml) prepared in citrate buffer (1% Citric acid and 1.46% Disodium hydrogen phosphate) at room temperature for 10 min. The reaction was stopped by adding 50 µl of 5 N Sulfuric acid. The absorbance was read at 492 nm in an ELISA plate reader (Spectramax). The reciprocal
20 of the highest serum dilution giving an optical density at least twice that given by the reagent blanks was taken as the ELISA end-point.

The antibody isotyping ELISAs were carried out in a similar fashion, except that in place of anti-mouse IgG-HRP conjugate, anti-mouse IgG1-HRP or the IgG2a-HRP conjugate (Pharmingen) was added. This was followed by the incubation with the
25 substrate and color development as above.

Example – 7

Plaque reduction neutralization assay: Two fold serial dilutions of sera from the immunized mice (starting from 1:10) were prepared in EMEM containing 5% FCS and antibiotics. Diluted sera were incubated at 56 °C for 30 min to inactivate the
30 complement. The serum sample (100 µl) was then mixed with equal volume of JEV culture supernatant containing 100 plaque-forming units (PFU) of the virus. The virus-antibody mixture was incubated at 37 °C for 1 hr before adding to a 35-mm dish containing ~70% confluent monolayer of PS cells. The plaque assay was carried out as

described. (43). Percent neutralization was calculated by counting the number of plaques in the presence and the absence of the mouse serum. All assays were done in duplicates. Reciprocal of the highest serum dilution giving 50% neutralization was taken as the JEV neutralization titer.

5 **Example – 8**

Cytokine ELISA: Spleen cell suspensions were prepared in RPMI 1640 supplemented with 10% FCS and 6×10^7 splenocytes were incubated with 3×10^7 PFU of JEV or *E. coli*-synthesized JEV E protein (10 µg/ml) in a 35-mm dish at 37 °C. Aliquots of culture supernatant were removed every day for the next 4 days and stored at -70 °C.

10 Interleukin (IL)-4, IL-5 and interferon (IFN)-γ were assayed using BD OptEIA kits (BD Biosciences) and as per the assay protocols.

Example – 9

Cytotoxic T lymphocyte (CTL) assay: Standard ^{51}Cr -release method as described previously (15) was used for the CTL assays with some modifications. Briefly, for
15 preparation of the responder cells, 3×10^7 splenocytes were incubated for 4 days with 3×10^7 PFU of JEV in a 35-mm dish in RPMI 1640 medium supplemented with antibiotics, 0.5 mM β-Mercaptoethanol, 0.32 mg/ml L-Glutamine, 0.1 mg/ml non-essential amino acids, 0.12 mg/ml Sodium pyruvate and 5% FCS at 37 °C. The cells thus generated were referred to as the effector cells. Virus-infected target cells were
20 prepared by infecting P388D1 cells with JEV for 48 hr at a MOI of 1 followed by incubation with 100 µCi of $\text{Na}_2^{51}\text{CrO}_4$ (NEN) and subsequent washings to remove free ^{51}Cr .

For carrying out the CTL assay, various numbers of effector cells were incubated at 37°C for 6 hr with 2×10^4 ^{51}Cr -labelled virus-infected cells by briefly centrifuging them
25 at 100 g for 4 min in a 96-well round bottom plate. At the end of the incubation period, 100 µl of cell-free supernatant was removed and the ^{51}Cr release was counted using a gamma counter (LKB). Triplicate estimations were done in all the assays and the percentage lysis was calculated using the following formula. Percent lysis = [(cpm released in the presence of effector cells – cpm released due to spontaneous leakage)/(total cpm released by 0.2% Triton X-100 lysis – cpm released due to
30 spontaneous leakage)] x 100.

Statistical analysis: The statistical significance of different findings between mouse groups was determined by Student's *t* test. $P \leq 0.05$ was considered to be significant.

Example – 10

Replication of RAds and synthesis of JEV proteins: The JEV E protein is 500 amino acids long membrane-anchored protein. We have earlier shown that deletion of the C-terminal 102 amino acids of JEV E protein leads to efficient secretion of the truncated protein into the cell surroundings (15). We had also shown that quality of immune responses in mice induced by the secretory E protein were different from those induced by the membrane-anchored E protein (15). Besides, vaccinia recombinants expressing the secretory E protein of Japanese encephalitis or Dengue viruses devoid of the membrane anchor sequence were found to be highly immunogenic in mice (14, 27, 37). We, therefore, constructed two recombinants, RAdEa synthesizing prM and Ea (full-length membrane-anchored JEV E protein) and RAdEs synthesizing prM and Es (398 amino acid secretory E protein). The JEV prM was included in our constructs as its co-synthesis was necessary for correct processing and folding of the E protein (18, 25). The presence of appropriate JEV cDNA in genomes of RAds was established by polymerase chain reaction using JEV genome sequence-specific oligonucleotide primers.

Replication of RAds was studied in HEK 293A cells infected at a MOI of 1. Figure 1 shows that a major burst in viral titers was observed both for RAdEa and RAdEs between 18 and 24 hr post-infection (PI) after which there was only a marginal increase in titers. RAdEs titer was ~40-fold higher than that of RAdEa at 24 hr PI. Following the virus replication, the cytopathic effects were first visible at 30 hr PI for both RAdEa and RAdEs. The cytopathic effects had become highly pronounced by 42 hr PI when almost 80% cells had come off the surface of the tissue culture plates. At this time point titer of RAdEs was 1.2×10^7 PFU/ml, which was 88-times higher than that of RAdEa. These results showed that compared to RAdEs, RAdEa replicated poorly in HEK 293A cells. We studied four independent isolates of RAdEa and found all them to be slow growers.

The synthesis of JEV proteins by RAds was studied in HEK 293A cells that were infected with different viruses followed by radiolabelling and immunoprecipitation of JEV proteins using mouse anti-JEV serum. Figure 2 shows that RAdEa-infected cell lysate had 2 proteins of apparent molecular masses of 51 and 23 kDa that corresponded with JEV E and prM proteins. None of these proteins were detectable in the culture supernatant of the infected cells. The RAdEs-infected cell lysate showed the synthesis

of Es and prM proteins of apparent molecular masses of 45 and 23 kDa, respectively. The culture supernatant from the RAdEs-infected cells had a significant amount of Es, indicating that the E protein synthesized by RAdEs was secretory.

5 Use of increased amounts of anti-JEV antibody and Protein A Sepharose in immunoprecipitations did not result in precipitation of enhanced amounts of E protein indicating that the amounts of these reagents used were not limiting. Scanning of the autoradiograph with optically-enhanced densitometer using 'Diversity One' software (version 1.6, PDI, New York) followed by calculations based on the volumes of the lysate or the supernatant loaded on the gel, suggested that the secretory E protein
10 present in the culture supernatant constituted about 76% of the total E protein synthesized by RAdEs-infected cells. Furthermore, levels of total Es protein synthesis were around 20-fold higher than the levels of Ea protein. Immunofluorescent staining of RAdEa- and RAdEs-infected HEK 293A cells further confirmed that levels of Ea protein were significantly lower than that of the Es protein (Figure 3). The lower levels
15 of Ea synthesis may be related to the poor growth of RAdEa in HEK 293A cells.

We found that RAdEa synthesizing the membrane-anchored E protein grew slowly and achieved 88-fold lower titers in HEK 293A cells when compared with RAdEs synthesizing the secretory E protein. Infection of HEK 293A cells with the recombinants followed by radioimmunoprecipitation of JEV proteins showed that
20 RAdEa synthesized lower amounts of JEV E protein. This was corroborated by the low levels of immunofluorescence on RAdEa-infected HEK 293A cells when compared with RAdEs-infected cells. HEK 293A cells support replication of E1-deleted RAds reported in this work as these cells contain Ad5 E1 transcription unit permanently integrated in them. In other mammalian cells these RAds are unable to replicate for the
25 want of the E1 sequences. However, expression of the foreign gene does take place, which is under the independent control of the CMV IE promoter. We have studied expression of JEV E protein by RAds in PS cells by immunofluorescence and radioimmunoprecipitation. No significant differences were found in the levels of E protein synthesis in PS cells infected with RAdEa or RAdEs at a MOI of 1.

30 The adenovirus vector used in our studies had deletions in both the E1 and E3 transcription units that allow packaging of up to 8 Kb foreign DNA in the recombinant virus. The size of JEV expression cassette inserted in RAdEa was ~3.3 Kb which was well within the packaging limits of the recombinant virus. The reason for lower titers of

RAdEa in HEK 293A cells is, thus, not clear. Previously, we found no differences in the levels of expression of membrane-anchored or secretory E protein of JEV when HEK 293A cells were transfected with expression plasmids containing the Ea or Es genes under CMV IE promoter (15). This observation together with our results in the PS cells on E protein synthesis indicates that lower levels of E protein synthesis by RAdEa in HEK 293A cells are related to the low levels of its replication.

Example – 11

Anti-JEV antibody response in mice immunized with RAdEs: Groups of BALB/c mice were immunized with RAdEa or RAdEs delivered orally or IM. The antibody response of these mice was compared with those immunized with formalin-inactivated commercial JEV vaccine. Serum samples collected from mice at various time points were assayed for anti-JEV end-point ELISA titers. Figure 4 shows that anti-JEV antibodies were detectable in all immunization groups on day 20 post-immunization and these titers increased further on days 28 and 44 post-immunization following the booster doses. Compared to IM immunization, antibody titers were drastically low in mice immunized orally with RAdEs. For example, compared to oral immunization, 1×10^8 PFU of RAdEs given IM induced ~60-fold higher antibody response on day 44. For both the oral as well as IM immunizations, higher antibody titers were obtained when higher doses of RAd were used. No significant differences were seen in day 44 anti-JEV antibody titers of mice immunized IM with 7.5×10^5 PFU of RAdEa or RAdEs. IM immunizations with RAdEs induced significantly higher antibody titers than those induced by IM inoculation of the vaccine. Thus, the lower dose of RAdEa and RAdEs (7.5×10^5 PFU) gave ~ 60-fold higher antibody titers after the second booster when compared with the titers obtained with the vaccine. At the higher dose of 1×10^8 PFU, RAdEs induced ~250-fold higher titers than the vaccine on day 44.

Some investigators have carried out oral immunization of mice with RAdEs using Sodium bicarbonate buffer to neutralize the acid pH of the stomach (11, 40, 47). However, there are others who have carried out oral immunization of mice with RAdEs without the use of any buffer (3, 9, 42, 48). We have compared the immunogenicity in mice of RAdEs given orally (1×10^8 PFU) with or without the bicarbonate buffer. Figure 4 shows that no advantage was offered by the use of bicarbonate buffer during oral immunization with RAdEs. In fact, no effect of booster doses was seen when RAdEs was delivered orally using bicarbonate buffer and antibody titers on day 44

post-immunization were lower than in those mice that received the virus without bicarbonate buffer.

Example – 12

Isotype analyses of anti-JEV antibody produced by immunized mice: In order to
5 analyze the quality of immune responses generated by the RAds, end-point titers of
anti-JEV IgG1 and IgG2a antibodies were determined by ELISA. Figure 5 shows that
at lower dose of RAds given orally (3×10^6 PFU) titers of anti-JEV IgG1 and IgG2a
antibodies were below 25. When a higher dose of RAdEs (1×10^8 PFU) was given
orally, the majority of antibodies were of IgG1 type; the ratio of IgG1/IgG2a titers in
10 this case was 6.48 indicating a Th2 type of immune response. When RAds were
delivered through IM route, the anti-JEV antibody response was almost exclusively of
IgG1 type. In case of mice immunized IM with RAdEa (7.5×10^5 PFU), IgG1/IgG2a
titer ratio was 68 and it was 64 in the case of RAdEs (7.5×10^5 PFU)-immunized mice.
At higher dose of 1×10^8 PFU, RAdEs again induced predominantly IgG1 type of anti-
15 JEV antibodies; the ratio of IgG1/IgG2a titers in this case was 25. These results
indicated that RAdEa and RAdEs induced an almost exclusive Th2 kind of immune
response in mice when delivered IM. The IM immunization of mice with the vaccine
also induced IgG1 dominated antibody response indicating a Th2 type immune
response.

Example – 13

JEV neutralizing antibody response in mice immunized with Rads: Titers of JEV
neutralizing antibodies were determined in serum samples obtained from the
immunized mice at day 44 post-immunization. Figure 6 shows that oral route of
immunization induced very low JEV neutralizing antibodies. Similar to ELISA titers,
25 the JEV neutralizing antibody titers were lower in mice immunized orally with RAdEs
plus the bicarbonate buffer compared to titers in those mice immunized with RAdEs
without the bicarbonate buffer, although the difference was statistically insignificant.
Compared to RAdEa, RAdEs given IM induced higher JEV neutralizing titers and these
were enhanced further when higher dose of virus was used for immunization. IM
30 immunization with RAdEs induced significantly higher JEV neutralizing antibody titers
than those induced by the vaccine.

Example – 14

Cytokine secretion by splenocytes from immunized mice: Splenocytes prepared from the immunized mice were cultured in presence of JEV and synthesis of IFN- γ , IL-4 and IL-5 was studied on each day for the next 4 days. Figure 7 shows that splenocytes from mice immunize with RAdEa or RAdEs by IM route secreted large amounts of IFN- γ . Splenocytes from mice immunized with the recombinant viruses through oral route made only small amounts of IFN- γ . Similarly, mice immunized with the vaccine made only small amounts of IFN- γ . Splenocytes from IM-immunized mice also made moderate amounts of IL-5 which was almost absent in the case of orally immunized mice or mice immunized with the vaccine. IL-4 was not detectable in any of the cases; the detection limit of IL-4 ELISA was 7.8 pg/ml. Similar pattern of cytokine secretion was observed when splenocytes were cultured in presence of JEV E protein

Example – 15

CTL activity in immunized mice: To study the generation of memory CTLs, splenocytes from immunized mice were stimulated *in vitro* with JEV and examined for cytotoxic activity against cells infected with JEV. Figure 8 shows the results of CTL assays at various effector to target cell ratios. Thus, mice immunized with RAdEa or RAdEs through IM route showed significant CTL activity. No CTL activity was detectable in mice immunized with RAdEa or RAdEs through oral route. Similarly, unimmunized and Ad5-immunized mice or those immunized with the vaccine showed no CTL activity.

Example – 16

Mice challenge studies: Mice immunized with RAdS were challenged at day 44 post-immunization by intra-cerebral inoculation of a lethal dose (100 LD₅₀) of JEV. These mice were observed for mortality for 3 weeks after the challenge. All mice immunized with 7.5×10^5 or 1×10^8 PFU of RAdEs given IM survived the challenge while none of the unimmunized mice survived. Furthermore, none of the mice immunized IM or orally with 1×10^8 PFU of E1/ E3 Ad5 survived the challenge. About 50-60% protection was seen in mice immunized with 1×10^8 PFU of RAdEs given orally. The level of protection was lower (30%) when mice were immunized orally with lower doses of RAdEs (3×10^5 PFU). The level of protection afforded by RAdEa immunization was very low; about 40% mice survived from those immunized with

7.5x10⁵ PFU given IM and only about 20% mice survived from the group immunized with 3x10⁶ PFU given orally. In a separate experiment, 15 mice were immunized with 1x10⁸ PFU of RAdEs and given 2 booster doses on day 21 and 35. When challenged on day 44 post-immunization with 1000 LD₅₀ of JEV, given intra-cerebral, 100% of the immunized mice survived.

The flavivirus E protein has been the antigen of choice for vaccine development using modern methods of vaccinology such as the DNA vaccination or the use of recombinant virus for antigen delivery (10, 12, 16, 28-31). This has been so because E protein plays an important role in a number of processes, including viral attachment, membrane fusion and entry into the host cell (26). Besides, flavivirus E protein induces virus-neutralizing antibodies and CTLs (14, 14, 15, 22, 23, 34). It has been shown that protection against JEV is mainly antibody dependent, and virus-neutralizing antibodies alone are sufficient to impart protection (19, 32). This was also implied from our previous observation that the formalin-inactivated JEV vaccine, which did not induce CTLs, provided protection to vaccinees against JEV (15). Thus, with a view to develop a recombinant virus-based JEV vaccine, we have constructed RAdEs synthesizing JEV E protein.

During replication of JEV, the E protein is expressed on the cell surface. Plasmid DNA vectors have been described that synthesize different forms of the E protein, such as the cytoplasmic, membrane-anchored or secretory (2, 6, 7, 15, 20). These different forms of JEV E protein were shown to induce different kind of immune responses. Similarly, recombinants of vaccinia expressing the secretory E protein of Japanese encephalitis or Dengue viruses were found to be highly immunogenic in mice (14, 27, 37). Previously, we had shown that truncated JEV E protein, where the membrane-anchor sequence had been removed by deletion of the C-terminal 102 amino acids, was actively secreted in the cell surroundings (15). We have now constructed RAdEs that synthesize the membrane-anchored or the secretory E protein.

Oral delivery of RAd has been shown to induce humoral and cellular immune responses to the protein encoded by the transgene, however, these responses have usually been weaker compared to those induced by the IM or intra-peritoneal delivery of RAd (21, 35, 42). In the present study too, oral immunization of mice by RAdEs resulted in significantly lower anti-JEV antibody titers when compared with the IM route of RAd delivery. Thus, mice immunized IM with 1x10⁸ PFU of RAdEs gave

~60-fold higher anti-JEV antibody response than those immunized with the same dose of the virus given orally.

Use of Sodium carbonate buffer to neutralize the pH of the stomach made no perceptible difference to antibody titers when compared with the antibody titers induced by RAdEs given orally without the bicarbonate buffer. In fact, when bicarbonate buffer was used during oral immunization, the booster doses of RAdEs failed to enhance the anti-JEV antibody titers. For RAdEa too, oral delivery resulted in weaker anti-JEV antibody responses compared to the IM delivery of the recombinant. Thus, compared to oral delivery, IM inoculation of 7.5×10^5 PFU of RAdEa (which was half the dose given orally) induced ~100-fold higher anti-JEV antibody titers. The antibody titers were dose dependent. Thus higher doses of RAdEs (1×10^8 PFU) delivered orally induced higher anti-JEV antibody titers. These titers were ~4-fold higher than those induced by the commercial vaccine given IM. Importantly, IM inoculation of RAdEa or RAdEs at both the doses tested (7.5×10^5 and 1×10^8 PFU) resulted in significantly higher antibody responses than those given by the vaccine; 1×10^8 PFU of RAdEs given IM induced ~250-fold higher titer than the vaccine. Similar pattern was reflected in JEV neutralizing antibody titers when oral route of RAds delivery was compared with the IM route although the differences weren't so pronounced. Thus ~20-fold higher JEV neutralizing antibody titers were induced by IM inoculation of 1×10^8 PFU of RAdEs compared to oral delivery of the recombinant. Only statistically insignificant differences were noted in anti-JEV antibody titers induced by 7.5×10^5 PFU of RAdEa and RAdEs given IM. However, there was significant difference in the JEV neutralizing antibody titers generated by the two RAds; a mean JEV neutralizing antibody titer of 10 was obtained when mice were immunized with RAdEa whereas it was 133 when mice were immunized with RAdEs. Higher JEV neutralizing antibody titers were recorded when higher doses of RAdEs were used for immunization. At both the doses tested (7.5×10^5 and 1×10^8 PFU) IM inoculation of RAdEs induced significantly higher JEV neutralizing antibody titers than the commercial vaccine. Thus a dose of 1×10^8 PFU of RAdEs given IM induced 8-fold higher JEV neutralization titer than the vaccine. These differences in JEV neutralizing antibody titers induced by RAdEa and RAdEs by oral and IM inoculation were reflected in the level of protection afforded by these recombinants to the immunized mice against lethal JEV challenge. Thus both doses of RAdEs inducing JEV

neutralizing antibody titers higher than the vaccine gave 100% protection. Immunization with RAdEs or RAdEa given orally gave only low levels of protection. Challenge experiments indicated that mice immunized IM with the adenovirus synthesizing the membrane-anchored form of JEV E protein did not develop protective immunity whereas those immunized with recombinant synthesizing the secretory form of JEV E protein developed robust anti-JEV protective immunity resulting in 100% protection. These results show that RAd-based JEV immunizations are superior to naked DNA immunizations, which imparted only about 50-60% protection in a mouse challenge model (15). It is interesting that level of protection was similar (50-60%) when mice were immunized with plasmid DNA synthesizing Ea or Es proteins (15) whereas in the present work Es induced significantly superior protective immune response than the Ea protein. This may be related to a more efficient delivery of JEV transgene using RAd than the direct injection of naked plasmid DNA for immunization. Our finding is, however, consistent with reports from others where truncated form of JEV or Dengue E protein (leading to its secretion) was found to be more immunogenic than the membrane-anchored form of the E protein (14, 37).

Poor anti-JEV antibody induction by oral immunization with RAdEs was also reflected in poor cytokine secretion by splenocytes in presence of JEV. While very little IFN- γ was secreted by splenocytes from mice immunized orally with RAdEs or RAdEa, significant amounts of IFN- γ were secreted by splenocytes obtained from mice immunized IM with RAdEa or RAdEs. Splenocytes from IM immunized mice also synthesized moderate amounts of IL-5 that was not detectable in cultures of splenocytes obtained from mice immunized orally with RAdEs. Mice immunized IM with both RAdEa and RAdEs had significant CTL activity, which was undetectable in mice immunized orally with RAdEs or IM with the vaccine. Oral immunization with RAdEs at lower dose resulted in IgG1 dominated immune responses; ratio of IgG1/IgG2a endpoint titers was 6.5. This is consistent with studies on oral immunization of mice with RAd synthesizing rabies glycoprotein where abundance of anti rabies IgG1 was recorded (46). The IM inoculation of RAdEa and RAdEs also resulted in preponderance of IgG1 kind of antibodies. No data could be found in literature on antibody isotypes when adenovirus recombinants are delivered IM. Our results indicating the preponderance of IgG1 type antibodies, secretion of IFN- γ and IL-5 by splenocytes and induction of CTLs suggest that IM inoculation of mice with RAdEs

synthesizing JEV E protein activates both the humoral and the cellular arms of the immune system, and immune responses of both Th1 and Th2 type are induced.

The results presented in this invention show that RAd synthesizing the secretory form of JEV E protein imparted robust immunity in mice against lethal dose of JEV given
5 intra-cerebral. This makes RAdEs a potential candidate vaccine against JEV. Further, safety profile of the vaccine of the instant application was studied. The vaccine is found to be safe for administration. None of the immunized mice showed any obvious complications.

Application Project

<120> Title : A recombinant vaccine against Japanese encephalitis virus (JEV) infection and a method thereof

<130> AppFileReference : IP 1340

<140> CurrentAppNumber : 1516/Del/2003

<141> CurrentFilingDate : 2003-12-04

Sequence

<213> OrganismName : Artificial Sequence

<400> PreSequenceString :

```

cgtaactata acggtcctaa ggtagcgaaa gctcagatct ggatctcccg atcccctatg   60
gtcgactctc agtacaatct gctctgatgc cgcatagtta agccagtatc tgctccctgc   120
ttgtgtgttg gaggtcgctg agtagtgcg cgagcaaat taagtacaa caaggcaagg   180
cttgaccgac aattgcatga agaactcgtc tagggttagg cgtttgcg cgcttcgca   240
tgtaggggac agatatacgc gttgacattg attattgact agttattaat agtaataat   300
tacgggggta ttagttcata gcccatatat ggagttccgc gttacataac ttacggtaaa   360
tggcccgctt ggctgaccgc ccaacgaccc ccgccattg acgtcaataa tgacgtatgt   420
tccatagta acgcaatag ggactttcca ttgacgtcaa tgggtggact attacggta   480
aactgccac ttggcagtac atcaagtgtg tcatatgcca agtacgccc ctattgacgt   540
caatgacggt aaatggccc cctggcatta tggccagtac atgacctat gggactttcc   600
tacttggcag tacatctacg tattagtcac cgtattacc atggtgagc ggttttggca   660
gtacatcaat gggcggtgat agcggttga ctacgggga ttacaagtc tccacccat   720
tgacgtcaat gggagttgt ttggcacca aaatcaacg gactttcaa aatgtcgtaa   780
caactccgc ccattgacg aaatggcgg taggcgtga cgggtggagg tctatataag   840
cagagctc tcgtaacta gagaacacac tgcctactgg ctatcgaaa ttaatacag   900
tcactatagg gagacccaag ctggctagcg tttaaacggg cccctagac tggagcggc   960
gocactgtgc tggatgacg gagctcgga ccatgtggct cgaagcttg gcagttgtca   1020
tagcttgccg agggagccatg aagttgtcga atttcagggg gaagctttg atgaccatca   1080
acaacacgga cattgcagac gttatcgtga ttccaccc caaaaggagag aacagatgct   1140
gggtccgggc aatcgacgtc ggttacatgt gtgaggacac catcacgtac gaatgtccta   1200
agcttactgc gggcaatgat ccagaggacg tggattgctg gtgtgacaac caagaagtct   1260
acgtccaata tggacgggtg acgcggacca ggcattccaa gcgaagcagg agatccgtgt   1320
cggtcagac acatggggag agttcactag tgaataaaa agaggcttgg ctggattcaa   1380
cgaaagccac acgatatctc acgaaaactg agaactggat cataaggaat cctggctatg   1440
ctttcttggc ggcggtactt ggtcggatgc ttggcagtaa caacgggtcaa cgcgtggtat   1500
ttaccatcct cctgctgttg gtcgctccgg ctacagttt taattgtctg ggaatgggca   1560
atcgcgactt catagaagga gccagtggag ccacttgggt ggacttgggt ctagaaggag   1620
atagctgttt gacaatcatg gcaaacgata aaccaacatt ggatgtccgc atgattaaca   1680
tcgaagctag ccaacttgct gaggtcagaa gttattgcta tcatgcctca gtcactgaca   1740
tctcgacggt ggctcgggtc cccatgactg gagaagctca caacgagaag cgagctgata   1800
gtagctatgt gtgcaaaaca ggcttcactg atcgtgggtg gggcaacgga tgggacttt   1860
tcgggaaggg aagcattgac acatgtgcaa aattctcctg caccagcaaa gcgattggga   1920
gaacaatcca gccagaaaac atcaatacag aagttggcat tttgtgcat ggaaccacca   1980
cttcggaaaa ccatgggaat tactcagcgc aagttggggc gtcccaggcg gcaaagtta   2040
ccgtaacacc caatgctcct tcgataacc tcaaacttgg tgactacgga gaagtcacac   2100
tggactgtga gccaaaggag ggactgaaca ctgaagcgtt ttacgtcatg accgtggggt   2160
caaagtcat tctggtccat agggatgggt ttcatgacct cgtctcccc tggacgtccc   2220
cttcgagcac agcgtggaga aacagagaac tctcatgga attgaagag gcgcacgcca   2280

```

caaaacagtc cgttgttgct cttggttcac aggaaggagg cctccatcag gcgttggcag 2340
 gagccatcgt ggtggagtac tcaagctcag tgaagttaac atcaggccac ctgaaatgta 2400
 ggctgaaaat ggacaaacta gctctgaaag gcacaaccta tggcatgtgt acagaaaaat 2460
 tctcgttcgc gaaaaatccg gcggacactg gtcacggaac agttgtcatt gaactctcct 2520
 actctgggag tgatggcccc tgcaaaattc cgattgtctc cgtcgcgagc ctcaatgaca 2580
 tgactcctgt tgggcggctg gtgacagtga acccctttgt cgcggcttcc agtgccaact 2640
 caaagggtct ggtcgagatg gaacccccct tcggagactc ctatatctgt gttggaagg 2700
 gagacaagca gatcaaccac cattggcaca aataataaag gatctgtgt tggccctcc 2760
 cccgtgcctt ccttgacctt ggaagggtcc actccactg tcttttcta ataaatgag 2820
 gaaattgcat cgcattgtct gagtaggtgt cattctattc tgggggtgg ggtggggcag 2880
 gacagcaagg gggaggattg ggaagacaat agcaggcatg ctggggatgc ggtgggctct 2940
 atggcttctg aggcggaaag aaccagcaga tctgcagatc tgaattcatc tatgtcgggt 3000
 gcgggagaaag aggtaatgaa atggcatcga ctggaagatc tgggcgtggt taagggtggg 3060
 aaagaatata taagggtggg gtcttatgta gttttgtatc tgttttcag cagccgccgc 3120
 cgccatgagc accaactcgt ttgatggaag cattgtgagc tcatatttga caacgcgcat 3180
 gcccccatgg gccgggggtg gtcagaatgt gatgggtccc agcattgatg gtcgccccgt 3240
 cctgcccgca aactctacta ccttgacctc cgagaccgtg tctggaacgc cgttggagac 3300
 tgcagcctcc gccccgctt cagccgctgc agccaccgcc cgcgggattg tgactgactt 3360
 tgccttctc agcccgctt caagcagtc agcttcccgt tcatccgcc gcgatgaca 3420
 gttgacggct ctttggcac aattggattc ttgaccgg gaactaatg tcttttca 3480
 gcagctgtg gatctgcgc agcagggttc tgcctgaag gcttctccc ctccaatgc 3540
 ggtttaaac ataaataaaa aaccagactc tgtttggatt tggatcaag aagtgtctg 3600
 ctgtcttat ttagggttt tgcgcgcgc gtaggcgcg gaccagcgt ctgcgtctt 3660
 gaggtctg tctattttt ccaggacgtg gtaaagtg ctctgagt tcaatacat 3720
 ggcataagc cgtctctgg ggtggagta gcaocactg agacttcat gctcgggg 3780
 ggtgtgtag atgacagc cgtagcagga gcctggcg tggctctaa aaatgtctt 3840
 cagtagcaag ctgattgca ggggcaggcc ctgtgtta gttttaca agcgttaag 3900
 ctggatggg tgcatactg gggatatgag atgcatctt gactgtatt ttagggtgc 3960
 tatgttcca gccatatcc tccgggatt catgtgtgc agaaccaca gcacagtga 4020
 tccgtgcac ttgggaaatt tgcattgtag cttagaagga aatgcgtga agaacttga 4080
 gacgccctg tgacctcaa gattttccat gcattcgtcc ataagatgg caatggccc 4140
 acgggcggcg gcctggcgga agatatttct gggatcacta acgtcatagt tgtgtccag 4200
 gatgagatc tcataggcca tttttacaa gcgcggcg aggggtccag actgcggtat 4260
 aatgggtcca tccggcccag gggcgtagt accctcacag atttgattt cccacgctt 4320
 gagttcagat ggggggatca tgtctacct ggggcgatg aagaaaacgg ttccgggg 4380
 aggggagatc agctgggaag aaagcagggt cctgagcagc tgcacttac cgcagccgt 4440
 gggcccgtaa atcacacta ttaccggctg caactggtg ttaagagagc tgcagctgcc 4500
 gtcatccctg agcagggggg ccacttctt aagcatgtcc ctgactcga tgttttcct 4560
 gacaaatcc gccagaaggc gctcggccc cagcgatagc agttcttga aggaagcaaa 4620
 gtttttaac gttttgagc cgtccgctt aggcattgt ttgagcgtt gaccaagcag 4680
 ttccaggcgg tccacagct cggtcactg ctctacgga tctgatcca gcatactcc 4740
 tcttttcgc ggttggggcg gcttctctg tacggcagta gtcgtgtct gtcagacgg 4800
 gccagggtca tgtcttcca cgggcgcagg gtcctctca gcgtagtct ggtcacgggt 4860
 aagggtgcg ctccggctg cgcgtggcc aggggtgcgt tgaggctggt cctgtgtgt 4920
 ctgaagcgt gccggtctt gccctgcgc tcggccagg agcatttgac catggtgtca 4980
 tagtccagcc cctccggcg gtcggcctt gcgcgcagct tgccttga ggaggcccg 5040
 cagaggggc agtgagact ttgagggcg tagagcttgg gcgcgagaaa taccgattcc 5100
 ggggagtagg catccgcgc gcaggcccc cagacggtct cgattccac gagccagggt 5160
 agcttggcc gttcgggtc aaaaaccagg ttcccccat gcttttcat gcgtttctta 5220
 cctctggtt ccatgagccg gtgtccacg tgggtgacga aaaggctgtc cgtgtcccc 5280

tatacagact tgagaggcct gtcctcgagc ggtgttccgc ggtcctcctc gtatagaac 5340
 tcggaccact ctgagacaaa ggctcgcgtc caggccagca cgaaggaggc taagtgggag 5400
 gggtagcggg cgttgtccac taggggggtcc actcgctcca ggggtgtgaag acacatgtcg 5460
 cccctctcgg catcaaggaa ggtgattggt tttaggtgt agggcacgtg accgggtgtt 5520
 cctgaagggg ggctataaaa ggggggtgggg gcgcgttcgt cctcactctc ttccgcatcg 5580
 ctgtctcga gggccagctg ttgggggtgag tactccctct gaaaagcggg catgacttct 5640
 gcgctaagat tgtcagtttc caaaaacgag gaggatttga tattcacctg gcccgcgggtg 5700
 atgcctttga ggggtggccgc atccatctgg tcagaaaaga caatctttt gttgtcaagc 5760
 ttgggtggca acgaccgta gagggcgttg gacagcaact tggcgatgga gcgcagggtt 5820
 tggttttgt gcgcatcggc gcgctccttg gccgcgatgt ttagctgcac gtattcgcgc 5880
 gcaacgcacc gccattcggg aaagacgggtg gtgcgctcgt cgggcaccag gtgcacgcgc 5940
 caaccgcggg ttgtcagggt gacaaggta acgctgggtg ctacctctcc gcgtaggcgc 6000
 tcgttggtcc agcagaggcg gccgcccttg cgcgagcaga atggcggtag ggggtctagc 6060
 tgcgtctcgt cgggggggtc tgcgtccacg gtaaaagacc cgggcagcag gcgcgcgtcg 6120
 aagtagtcta tcttgcaccc ttgcaagtct agcgctgct gccatgcgcg ggccgcaagc 6180
 gcgcgctcgt atgggttgag tgggggaccc catggcatgg ggtgggtgag gcggaggcg 6240
 tacatgccgc aaatgtcgt aacgtagagg ggctctctga gtattccaag atatgtaggg 6300
 tagcatcttc caccgcggat gctggcgcgc acgtaatcgt atagttcgtg cgaggggagcg 6360
 aggaggtcgg gaccgaggt gctacgggcg ggctgctctg ctggaagac tatctgcctg 6420
 aagatggcat gtgagttgga tgatatggtt ggacgctgga agacgttgaa gctggcgtct 6480
 gtgagacctt ccgcgtcacg cacgaaggag gcgtaggagt cgcgcagctt gttgaccagc 6540
 tcggcgggtg cctgcacgtc tagggcgagc tagtccaggg ttctcttgat gatgtcatc 6600
 ttatctgtc cctttttt ccaagctcg cggttgagga caaactcttc gcggtctttc 6660
 cagtactctt ggataggaaa cccgtcggcc tccgaacggt aagagcctag catgtagaac 6720
 tgggtgacgg cctggtaggc gcagcatccc ttttctacgg gtacgcgta tgcctgcgcg 6780
 gccctccgga gcgagggtg-ggtgagcgca aagggtgccc tgaccatgac tttaggtac 6840
 tggatttga agtcagtgct gtcgcatccg cctgctccc agagcaaaaa gtccgtgcgc 6900
 tttttgaa gcggatttgg cagggcgaag gtgacatcgt tgaagagtat ctttcccgcg 6960
 cgaggcataa agttgcgtgt gatgcggaag ggtcccggca cctcggaacg gttgttaatt 7020
 acctgggcgg cgagcacgat ctgctcaaag ccgttgatgt tgtggccac aatgtaagt 7080
 tccaagaagc gcgggatgcc cttgatgaa ggcaattttt taagttctc ttaggtgagc 7140
 tcttcagggg agctgagccc gtgctctgaa agggccaggt ctgcaagatg agggttgaa 7200
 gcgacgaatg agctccacag gtcacgggcc attagcattt gcagggtgtc gcgaagggtc 7260
 ctaaactggc gacatagggc cttttttt ggggtgatgc agtagaagg aagcgggtct 7320
 tgttccagc ggtccatcc aaggttcgcg gctaggcttc gcgcggcagt cactagaggc 7380
 tcatctccg cgaactcat gaccagcatg aagggcacga gctgctccc aaaggcccc 7440
 atccaagtat aggtctctac atcgtagggtg acaaaagac gtcgggtgcg aggatgcgag 7500
 ccgacggga agaactggat ctcccgccac caattggagg agtggctatt gatgtggtga 7560
 aagtagaagt ccctgcgacg ggccgaacac tcgtgctggc ttttgtaaaa acgtgcgag 7620
 tactggcagc ggtgcacggg ctgtacatcc tgacgaggt tgacctgacg accgcgcaca 7680
 aggaagcaga gtgggaattt gagcccctcg cctggcgggt ttggctggtg gtcttctact 7740
 tcggctgctt gtccttgacc gtctggctgc tcgaggggag ttacgggtgga tcggaccacc 7800
 acgccgcgcg agcccaaagt ccagatgtcc gcgcgcggcg gtcggagctt gatgacaaca 7860
 tcgcgcagat gggagctgtc catggtctgg agctcccgcg gcgtcaggtc aggcgggagc 7920
 tcctgcaggt ttacctcga tagacgggtc agggcgcggg ctatgccag gtgataccta 7980
 atttcagggg gctggttggg ggcgcgctcg atggcttga agaggccgca tccccgggc 8040
 gcgactacgg taccgcgcgg cgggcggtgg gcccgggggg tgccttga tgatcatct 8100
 aaaagcgggt acgcgggcga gccccggag gtgggggggg ctccggacc gccgggagag 8160
 ggggcagggg cacgtcggcg ccgcgcggg gcaggagctg gtgctgcgcg cgtaggttgc 8220
 tggcgaacgc gacgacgcgg cggttgatct cctgaatctg gcgcctctgc gtgaagacga 8280

cgggccccgt gagcttgaac ctgaaagaga gttcgacaga atcaatttcg gtgtcgttga 8340
 cggcgccctg gcgcaaaatc tcctgcacgt ctctgagtt gtcttgatag gcgatctcgg 8400
 ccatgaactg ctgactctct tcctcctgga gatctccgcg tccggctcgc tccacggtgg 8460
 cggcgagggtc gttggaatg cgggccatga gctgcgagaa ggcgttgagg cctccctcgt 8520
 tccagacgcg gctgtagacc acgccccctt cggcatcgcg ggcgcgcatg accacctcgc 8580
 cgagattgag ctccacgtgc cgggcgaaga cggcgtagtt tcgaggcgcg tgaagagggt 8640
 agttgagggt ggtggcgggtg tgttctgcca cgaagaagta cataaccag cgtcgcaacg 8700
 tggattcgtt gatacccc aaggcctcaa ggcgtccat ggcctcgtag aagtcacgg 8760
 cgaagttgaa aaactgggag ttgcgcgcg acacgggttaa ctctcctcc agaagacgga 8820
 tgaagtcggc gacagtgtcg gcacacctcg gctcaaggc tacagggggc tcttcttct 8880
 cttaactct ctctccata agggcctccc ctctcttct tctggcggc ggtgggggag 8940
 gggggacacg gggcgacga cggcgaccg ggaggcggc gacaaagcg tcgatcatct 9000
 ccccgcgcg acggcgcatg gtctcgggtga cggcgcgcc gtctcgcgg gggcgagtt 9060
 ggaagacgcc gccgctcatg tcccgggtat gggttggcgg ggggctgcca tgcggcaggg 9120
 atacggcgt aacgatgat ctcaacaatt gttgttagg tactccgcg ccgagggacc 9180
 tgagcgagtc cgcacgacc ggatcgga aaacctcgag aaaggcgtct aaccagtcac 9240
 agtcgcaagg taggctgagc accgtggcgg cggcgacggc ggcgggctcg gggttgttct 9300
 tggcggagggt gctgctgatg atgtaattaa agtaggcggt cttagacgg cgatggctcg 9360
 acagaagcac catgtcctg ggtccggcct gctgaatgcg caggcggctg gccatgcccc 9420
 aggtctcgtt ttgacatcg cgcaggtctt ttagtagtc ttgcatgagc ctctctaccg 9480
 gcactcttc tctcctcc tctgtctg catctctgc atctatcgt cggcgcgcg 9540
 cggagtttg cgttaggtgg cgcctcttc ctccatgcg tgtgacccg aagccccca 9600
 tcggctgaag cagggtcagg tcggcgacaa cgcgctcggc taatatggc tctgcacct 9660
 gcgtgagggt agactggaag tcactcatgt ccacaaagc gtggtatgc cccgtgttga 9720
 tgggttaagt gcagttggc ataacggacc agttaacgt ctggtgacc ggctgcgaga 9780
 gctcgggtga cctgagacg gagtaagccc tcagtcaca tactagtcg ttgcaagtc 9840
 gcaccaggta ctggtatccc accaaaaagt ggcggcgcg ctggcggtag aggggcccagc 9900
 gtaggggtggc cggggctccg gggcgagat ctccaacat aaggcgatga tatccgtaga 9960
 tgtacctgga catccagggt atgcggcgcg cgggtgggga ggcgcgcca aagtcgcgga 10020
 cgcgggtcca gatgttgcg agcgcaaaa agtctccat ggtcgggacg ctctggccgg 10080
 tcaggcgcg gcaatcgtg acgctctagc gtcaaaaagg agagcctgta agcgggcact 10140
 ctccgtggt ctggtggata aattcgcaag ggtatcatg cggacgaccg gggttcagc 10200
 cccgtatccg gccgtccgc gtgatcatg cggttaccg ccgctgtcg aaccagggtg 10260
 tgcgacgtca gacaacgggg gagtgctct tttggcttc tccaggcgc ggcggctgct 10320
 gcgctagctt tttggccac tggccgcgc cagcgtaagc ggttaggctg gaaagcgaaa 10380
 gcattaagt gctcgtccc ttagccgga gggttatctt ccaagggtg agtcgcgga 10440
 cccccgttc gagtctcga ccggccggac tgcggcgaac gggggtttgc ctccccgtca 10500
 tgcaagacc cgttgcaaa ttctccgga aacagggacg agccccctt ttgctttcc 10560
 cagatgcatc cgtgtctcg gcagatgcg cccctcttc agcagcggc agagcaagag 10620
 cagcggcaga catgagggc accctcccct cctctaccg cgtcaggagg ggcgacatcc 10680
 gcgggtgacg cggcagcaga tgggtattac gaacccccg ggcgcgggc ccggcactac 10740
 ctggacttg aggaggcgga gggcctggcg cggctaggag cgcctctcc tgagcggcac 10800
 ccaagggtgc agctgaagcg tgatagcgt gaggcgtacg tgcccgcgca gaacctgtt 10860
 cgcgaccgcg agggagagga gcccaggag atgcgggac gaaagtcca cgcaggcgcg 10920
 gagctggcg atggcctgaa tcgcgagcg tgcgtgcgc agggaggact tgagcccgac 10980
 gcgcgaaccg ggattagtcc cgcgcgcga cagtgggcg ccgccacct ggtaaccgca 11040
 tacgagcaga cgtgaacca ggagattaac ttcaaaaaa gctttaaca ccacgtgct 11100
 acgctgtgg cgcgcgagga ggtggctata ggactgatg atctgtggga ctttgaagc 11160
 gcgctggagc aaaaccaaa tagcaagccg ctcatggcg agctgttct tatagtgcag 11220
 cacagagggg acaacaggc attcagggat gcgctgctaa acatagtaga gcccaggggc 11280

cgctggctgc tcgatttgat aaacatcctg cagagcatag tggcgagga gcgcagcttg 11340
 agcctggctg acaagggtggc cgccatcaac tattcatgc ttgcctggg caagttttac 11400
 gcccgcaaga tataccatac cccttacgt cccatagaca aggaggtaaa gatcaggggg 11460
 ttctacatgc gcatggcgct gaagggtctt accttgagcg acgacctggg cgtttatcgc 11520
 aacgagcgca tccacaaggc cgtgagcggt agccggcggc gcgagctcag cgaccgcgag 11580
 ctgatgcaca gcctgcaaaag ggccctggct ggacgggca gcggcgatag agaggccgag 11640
 tcctactttg acgcgggcg ctagctgcgc tgggccccaa gccgacgcgc cctggaggca 11700
 gctggggccg gacctgggt ggccggggca ccgcgcgcgc ctggcaactg cggcgcgctg 11760
 gaggaatatg acgaggacga tgagtacgag ccagaggacg gcgagtacta agcgggtgatg 11820
 tttctgatca gatgatgcaa gacgcaacgg acccggggt gcggcgcggc ctgcagagcc 11880
 agccgtccgg ccttaactcc acggagcact ggcccgaggt catggaccgc atcatgtcgc 11940
 tgactgcgcg caatcctgac gcgttcggc agcagccgca ggccaaccgg ctctccgcaa 12000
 ttctggaagc ggtgggtccg gcgcgcgcaa accccacgca cgagaagggt ctggcgatcg 12060
 taaacgcgct ggccgaaaac agggccatcc ggcccgacga ggccggcctg gtctacgacg 12120
 cgctgcttca gcgcgtggct cgttacaaca gcggcaactg gcagaccaac ctggaccggc 12180
 tgggtggggga tgtgcgcgag gccgtggcg agcgtgagcg gcgcgagcag cagggcaacc 12240
 tgggtcccat ggttgacta aacgccttc tgagtacaa gcccgccaac gtgcccggg 12300
 gacaggagga ctacaccaac ttgtgagcg cactgcggct aatggtgact gagacaccgc 12360
 aaagtggagt gtaccagtct ggccagact atttttcca gaccagtaga caaggcctgc 12420
 agaccgtaaa cctgagccag gctttcaaaa acttcagggt gctgtggggg gtgcgggctc 12480
 ccacaggcga ccgcgcgacc gtgtctagct tgcgacgccc caactcgcgc ctgtgtctgc 12540
 tgctaatagc gcccttcacg gacagtggca gcgtgtccg ggacacatac ctaggctact 12600
 tgctgacact gtaccgcgag gccataggct aggcgcagt ggacgagcat actttccagg 12660
 agattacaag tgcagccgc gcgtggggc agggaggac ggagcagctg gaggcaacc 12720
 taaactacct gctgaacaac cggcggcaga agatccctc gttgcacagt ttaaacagcg 12780
 agggaggagc cattttgcgc tacgtgcagc agagcgtgag ccttaacctg atgcgcgacg 12840
 gggtaacgcc cagcgtggcg ctggacatga ccgcgcgcaa catggaaccg ggcatgtatg 12900
 cctcaaaccg gccgtttatc aaccgcctaa tggactact gcatcgcgcg gccgccgtga 12960
 accccgagta ttaccacat gccatctga accgcactg gctaccgcc cctggtttct 13020
 acaccggggg attcagggtg cccgagggtg acgatggatt cctctgggac gacatagacg 13080
 acagcgtgtt ttccccgcaa ccgagaccc tgcagaggtt gcaacagcgc gagcaggcag 13140
 aggcggcgct gcgaaaggaa agcttccgca ggccaagcag ctgtccgat ctaggcgctg 13200
 cggccccgcg gtcagatgct agtagccat ttccaagctt gatagggtct ctaccagca 13260
 ctgcaccac ccgccccgcgc ctgctggcg aggaggagta cctaaacaac tcgctgctgc 13320
 agccgcagcg cgaaaaaac ctgcctccg catttccaa caacgggata gagacctag 13380
 tggacaagat gagtagatgg aagacgtacg cgaggagca cagggacgtg ccaggcccgc 13440
 gcccgccac ccgtcgtcaa aggcacgacc gtcagcggg tctggtgtgg gaggacgatg 13500
 actggcaga gcacagcagc gtctggatt tgggaggggg tggcaaccg ttgcgcacc 13560
 ttccccag gctggggaga atgttttaa aaaaaaaaa gcatgatgca aataaaaaa 13620
 ctaccaaagg ccatggcacc gagcgttggg ttcttgtat tcccctagt atgcggcgcg 13680
 cggcgatgta tgaggaaagg cctcctccct cctacgagag tctggtgagc gcggcgccag 13740
 tggcgcggc gctgggttct cctctgatg cctccctgga ccgcccgtt gtgcctccgc 13800
 ggtacctgcg gcctaccggg gggagaaaca gcatccgtta ctctagttg gcaccctat 13860
 tcgacaccac ccgtgtgtac ctgggtggca acaagtcaac ggatgtggca tccctgaact 13920
 accagaacga ccacagcaac ttctgacca cggctattca aaacaatgac tacagcccgg 13980
 gggagggaag cacacagacc atcaatctg acgaccggc gcactggggc ggcgacctga 14040
 aaaccatct gcataccaac atgccaatg tgaacgagtt catgtttacc aataagtta 14100
 aggcgcgggt gatggtgtcg gccttccta ctaaggcaa tcaggaggag ctgaataacg 14160
 agtgggtgga gttcacgctg cccgagggca actactccga gacctgacc atagacctta 14220
 tgaacaacgc gatcgtggag cactactga aagtgggag acagaacggg gttctggaaa 14280

gcgacatcgg ggtaaagttt gacacccgca acttcagact ggggtttgac cccgtcactg 14340
 gtcttgtcat gcctggggta tatacaaacg aagccttcca tccagacatc attttgtcgc 14400
 caggatgcgg ggtggacttc acccagagcc gcctgagcaa ctgttgggc atccgcaagc 14460
 ggcaaccctt ccaggaggcg ttaggatca cctacgatga tctggagggt ggtaacattc 14520
 ccgactgtt ggatgtggac gcctaccagg cgagcttgaa agatgacacc gaacaggcg 14580
 ggggtggcgc aggcggcagc aacagcagtg gcagcggcgc ggaagagaac tccaacgcgg 14640
 cagccgcggc aatgcagccg gtggaggaca tgaacgatca tgccattcgc ggcgacacct 14700
 ttgccacacg ggctgaggag aagcgcgctg aggcggaagc agcggccgaa gctccgccc 14760
 ccgctgcgca acccgagggtc gagaagcctc agaagaaacc ggtgatcaaa cccctgacag 14820
 aggcagcga gaaacgcagt tacaacctaa taagcaatga cagcaccttc acccagttac 14880
 gcagctggta ccttgcatc aactacggcg accctcagac cggaatccgc tcatggaccc 14940
 tgctttgcac tctgacgta acctgcggct cggagcaggt ctactggtcg ttgcagaca 15000
 tgatgcaaga cccgtgacc ttccgctcca cgcgcagat cagcaacttt ccggtggtgg 15060
 gcgcgagct gttgcccgtg cactccaaga gcttctaca gaccaggcc gtctactccc 15120
 aactatccg ccagtttacc tcttgaccc acgtgttcaa tcgctttccc gagaaccaga 15180
 ttttggcgcg cccgccagcc ccacatca ccacgtcag tgaacaggt cctgcttca 15240
 cagatcacgg gacgtaccg ctgcgcaaca gcatcggagg agtccagcga gtgaccatta 15300
 ctgacgccag acgcccaccc tgcccctacg ttacaaggc cctgggcata gtctcgccg 15360
 gcgtcctatc gagccgact tttgagcaa gcatgtccat ccttatcgc cccagcaata 15420
 acacaggctg gggcctgcgc ttccaagca agatgtttgg cggggccaag aagcgtccg 15480
 accaacaccc agtcgcgtg cgcgggcact accgcgcgcc ctggggcgcg cacaacgcg 15540
 gccgactgg gcgcaccacc gtcgatgacg ccatcgacgc ggtggtggag gaggcgcga 15600
 actacacgcc cagccgcca ccagtgtcca cagtggacgc ggccattcag accgtggtgc 15660
 gcggagccc gcgtatgtt aaaatgaaga gacggcgag gcgcgtagca cgtcgccacc 15720
 gcgcgcgacc cggcactgac gccaacgcg cggcgccggc cctgcttaac cgcgcagtc 15780
 gcacggccg acggcgccg atgcggccg ctgaaaggct ggccgagggt attgtcactg 15840
 tgccccccag gtccaggcga cagcggccg ccgcagcagc cgcggccatt agtctatga 15900
 ctcagggtcg caggggcaac gtgtattggg tgcgcgactc ggttagcggc ctgcgcgtgc 15960
 ccgtgcgcac ccgcccccg cgcaactaga ttgcaagaaa aaactactta gactcgtact 16020
 gttgtatgta tccagcggcg gcggcgcgca acgaagctat gtccaagcgc aaaatcaag 16080
 aagagatgct ccaggatc gcgcgggaga tctatggccc ccgaagaag gaagagcagg 16140
 attacaagcc ccgaaagcta aagcgggtca aaaagaaaaa gaaagatgat gatgatgaac 16200
 ttgacgacga ggtggaactg ctgcacgcta ccgcgccag gcgacgggta cagtggaaag 16260
 gtcgacgcgt aaaacgtgtt ttgcgacccg gcaccaccgt agtctttacg cccgtgagc 16320
 gctccaccg cacctacaag gcgtgtatg atgagggtga cggcgacgag gacctgctg 16380
 agcaggccaa cgagcgctc ggggagtttg cctacggaaa gcggcataag gacatgctg 16440
 cgttgcgct ggacgaggcg aaccaacac ctagcctaaa ccccgtaaca ctgcagcagg 16500
 tgctgccgc gcttgaccg tccgaagaaa agcgcggcct aaagcgcgag tctggtgact 16560
 tggcaccac cgtgcagctg atggtacca agcgcagcg actggaagat gtcttgaaa 16620
 aaatgaccgt ggaacctggg ctggagccc aggtccgct gcggccaatc aagcaggtg 16680
 cgccgggact gggcgtgag accgtggagc ttacagatac cactaccagt agcaccagta 16740
 ttgccaccg cacagaggcg atggagacac aaacgtcccc ggttgccca gcggtggcg 16800
 atgccggtg gcagcgggtc gtcggggcg cgtccaagac ctctacggag gtgcaaacgg 16860
 accgtggat gtttcgctt tcagcccc ggcccccgc cggttcgagg aagtacggcg 16920
 ccgcagcgc gctactgccc gaatatgccc tacatcctc cattgcgct accccggct 16980
 atcgtggcta cacctaccg ccagaagac gagcaactac ccgacgcga accaccag 17040
 gaaccgccc ccgctgcgc cgtcgccagc ccgtgctggc ccgatttcc gtgcgaggg 17100
 tggctcgca aggaggcagg accctggtg tgcacacgc gcgctaccac cccagcatcg 17160
 ttaaaagcc ggtcttttg gttcttcag atatggcct cacctgccg ctcggtttcc 17220
 cgggtccggg attccagga agaatgacc gtaggagggg catggccggc cagggcctga 17280

cgggaggcat ggcgtgtg caccaccggc ggccggcgcg gtcgcaccgt cgcgtgctgc 17340
 gcggatcctt gcccctcctt attccactga tcgcccggc gattggcgcc gtgcccggaa 17400
 ttgcatccgt ggccttgag gcgcagagac actgattaaa aacaagttgc atgtggaaaa 17460
 atcaaaataa aaagtctgga ctctacgct cgttggtcc tgtaactatt ttgtagaatg 17520
 gaagacatca actttgctc tctggcccc cgacacggct cgcgccgtt catgggaac 17580
 tggcaagata tcggcaccag caatatgagc ggtggcgct tcagctgggg ctgctgtgg 17640
 agcggcatta aaaatttcgg ttccaccgtt aagaactatg gcagcaaggc ctggaacagc 17700
 agcacaggcc agatgctgag ggataagttg aaagagcaaa atttcaaca aaagggtgta 17760
 gatggcctgg cctctggcat tagcgggggtg gtggacctgg ccaaccaggc agtgcaaat 17820
 aagattaaca gtaagcttga tccccgcct ccctagagg agcctccacc ggccgtggag 17880
 acagtgtctc cagagggcg tggcgaagag cgtccgccc ccgacaggga agaaactctg 17940
 gtgacgcaaa tagacgagcc tccctgtac gaggaggcac taaagcaagg cctgccacc 18000
 accgtccca tcgcccct ggctaccgga gtgctggcc agcacacacc cgtaacgtg 18060
 gacctgctc cccccccga caccagcag aaacctgtgc tgcaggccc gaccgccgtt 18120
 gttgtaacc gtctagccg cgcgtccctg cgcgcgccg ccagcggctc gcgacgtt 18180
 cggccgtgag ccagtggcaa ctggcaagc aactgaaca gcacgtggg tctgggggtg 18240
 caatccctga agcggcgac atgcttctga tagtaactg gtcgtatgtg tgtcatgtat 18300
 gcgtccatgt cgcgccaga ggagctgctg agccgccgc cgcgcctt ccaagatggc 18360
 tacccttcg atgatccgc agtggctta catgcacatc tcgggccagg acgctcggg 18420
 gtacctgagc cccgggctg tcagtttgc ccgcgccacc gagacgtact tcagcctgaa 18480
 taacaagttt agaaaccca cgtggcgcc tacgcagac gtgaccacag accggtccca 18540
 gcgttgacg ctgcggttca tccctgtgga ccgtgaggat actgctact cgtacaaggc 18600
 gcggttacc ctagtgtgg gtgataaccg tgtgctggac atggctcca cgtacttga 18660
 catccggcg gtgctggaca ggggocctac ttttaagccc tactctggca ctgctcaaa 18720
 cgccctggct cccaagggtg cccaatcc ttgcgaatgg gatgaagctg ctactgctt 18780
 tgaataaac ctagaagaag aggcagatga caacgaagc gaagtagac agcaagctga 18840
 gcagcaaaa actcacgtat tgggcaggc gccttattct ggtataaata ttacaagga 18900
 gggatttcaa atagggtgc aaggtaaac acctaatat gccgataaaa cattcaacc 18960
 tgaacctcaa ataggagaat ctgagtggta cgaacagaa attaatcatg cagctgggag 19020
 agtccataaa aagactaccc caatgaaacc atgttaccgt tcatatgcaa aaccacaaa 19080
 tgaatatgga gggcaaggca ttctgtgtaa gcaacaaat ggaagctag aaagtcaagt 19140
 ggaaatgcaa ttttctcaa ctactaggc agccgaggc aatgggtata actgactcc 19200
 taaagtggta ttgtacagtg aagatgtaga tatagaacc ccagacatc atatttcta 19260
 catgcccact attaaggag gtaactcacg agaactaat ggccaacat ctatgccc 19320
 caggcctaatac atttgctt ttagggacaa ttttattgt ctaattattt acaacagcac 19380
 gggtaatatg ggtgttctg cgggccaagc atcgagttg aatgctgtg tagatttga 19440
 agacagaac acagagctt cataccagct ttgcttgat tccattggg atagaaccag 19500
 gtactttct atgtggaatc aggtgttga cagctatgat ccagatgta gaattattga 19560
 aaatcatgga actgaagatg aacttccaa ttactgctt ccactgggag gtgtgattaa 19620
 tacagagact ctacaaagg taaaacctaa aacaggctag gaaatggat gggaaaaaga 19680
 tgctacagaa ttttcagata aaaatgaaat aagagttgga aataatttg ccatggaaat 19740
 caatctaat gccaacctgt ggagaaattt cctgtactcc aacatagcg tgtatttgc 19800
 cgacaagcta aagtacgtc ctccaactg aaaaatttct gataaccaa acactacga 19860
 ctacatgaac aagcagtggt tggctccgg gctagtggac tgctacatta accttggagc 19920
 acgtgtgtcc ctgactata tggacaact caaccattt aaccaccac gcaatgctg 19980
 cctgcgtac cgtcaatgt tgctgggcaa tggctgctat gtgcccctcc acatccagg 20040
 gcctcagaag ttcttgcca ttaaaaacct ctttctctg ccgggctcat acactacga 20100
 gtggaacttc aggaaggatg itaatgggt tctgcagagc tccctaggaa atgacctaag 20160
 ggttgacgga gccagcatta agtttgatag catttgctt tacgccact tcttcccat 20220
 ggcccacaac accgctcca cgcttggagc catgctaga aacgacacca acgaccagt 20280

cttaacgac tatctctccg ccgccaacat gctctaccct ataccgcca acgctacca 20340
 cgtgccata tccatccctt ccgcaactg ggcggctttc cgcggctggg ccttcacgcg 20400
 ccttaagact aaggaaaccc catcactggg ctggggctac gacccttatt acacctactc 20460
 tggctctata ccttacctag atggaacctt ttacctcaac cacaccttta agaagggtggc 20520
 cattaccttt gactcttctg tcagctggcc tggcaatgac cgcctgctta cccccaacga 20580
 gtttgaatt aagcgtcag ttgacgggga gggttacaac gtigcccagt gtaacatgac 20640
 caaagactgg ttctgggtac aaatgctagc taactataac attggctacc agggcttcta 20700
 tatcccagag agctacaagg accgcatgta ctcttcttt agaaacttc agcccatgag 20760
 ccgtcaggtg gtggatgata cttaatacaa ggactacca caggtgggca tcttaccca 20820
 acacaacaac tctggatttg ttggctacct tgcctccacc atgcgcgaag gacaggccta 20880
 ccttgctaac ttcccctatc cgcttatagg caagaccgca gttgacagca ttaccagaa 20940
 aaagtcttct tgcgatcgca cccttggcg catccattc tccagtaact ttatgtccat 21000
 gggcgcactc acagacctgg gccaaaacct tctctacgcc aactccgccc acgcgctaga 21060
 catgactttt gaggtggatc ccatggacga gccaccctt cttatgttt tgtttgaagt 21120
 ctttgacgtg gtccgtgtgc accagccgca ccgcgcgctc atcgaaacgg tgtacctgcg 21180
 cagcccttc tcggccggga acgccacaac ataaagaagc aagcaacatc aacaacagct 21240
 gccgcatagg gctccagtga gcaggaactg aaagccattg tcaagatct tgggtgtggg 21300
 ccatatcttt tgggcacctg tgacaagcg tttccaggct ttgtttctcc acacaagtc 21360
 gcctgcgcca tagtcaatac ggccggtgcg gagactgggg gcgtacactg gatggccttt 21420
 gcctggaacc cgcactcaaa aacatgctac ctcttgagc ccttggctt ttctgaccag 21480
 cgactcaagc aggtttacca gtttgagtac gactcactcc tgcgccgtag cgcattgct 21540
 tcttccccg accgctgtat aacgctggaa aagtcacccc aaagcgtaca ggggcccac 21600
 tcggccgctt gtggactatt ctgctgcatg ttctccacg cctttgcca ctggcccca 21660
 actccatgg atcaacaacc caccatgaac ctattaccg gggtaacca ctccatgctc 21720
 aacagtcctt aggtacagcc caacctgct cgaaccagg aacagctcta cagcttctg 21780
 gagcgccact cgcctactt ccgcagocac agtgcgcaga ttaggagcgc cacttcttt 21840
 tgtcatgta aaaacatgta aaaataatgt actagagaca cttcaataa aggcaaatgc 21900
 tttatttgt acactctcg gtgattattt accccaccc ttgccgtctg cgccgtttaa 21960
 aaatcaagg ggttctgccc gcctatgcta tgcgcactg gcaggagac gttgcgatac 22020
 tgggtgttag tgtccactt aaactcaggc acaaccatcc gcggcagctc ggtgaagttt 22080
 tcactccaca ggctgcgcac catccaac gcgtttagca ggtcgggcgc cgatatcttg 22140
 aagtcgagc tggggcctcc gccctgcgcg cgcgagttgc gatacacagg gttgcagcac 22200
 tggaaacta tcagcgccgg gtggtgcacg ctggccagca cgtcttgc ggagatcaga 22260
 tccgctcca ggtcctccg gttgctcagg gcgaacggag tcaacttgg tagctgcctt 22320
 cccaaaaagg gcgctgccc aggccttgag ttgactcgc accgtagtgg catcaaaagg 22380
 tgaccgtgcc cggctgggc gttaggatac agcgctgca taaaagcctt gatctgctta 22440
 aaagccacct gagccttgc gcctcagag aagaacatgc cgaagactt gccgaaaac 22500
 tgattggccg gacaggccgc gtcgtgcacg cagcaccttg cgtcgggtgt ggagatctgc 22560
 accacattc gggccaccg gttcttcacg atcttggcct tctagactg ctcttcagc 22620
 ggcgcgtgcc cgttttgcct cgtcacatcc attcaatca cgtgtcctt attatcata 22680
 atgcttccgt gtagacatt aagctgcct tcgatctcag cgcagcggg cagccacaac 22740
 gcgcagccc tgggctcgtg atgctttag gtcaccttg caaacgactg caggtacgcc 22800
 tgcaggaatc gcccacatc cgtcacaag gcttcttgc tggtaagggt cagctgcaac 22860
 ccgcggtgct cctcgttcag ccaggcttg catagggcg ccagagctt cacttggta 22920
 ggagtagtt tgaagttcgc ctttagatcg ttatccacgt ggtacttgc catcagcgcg 22980
 cgcgcagcct ccatgccctt cttccagca gacacatcg gcacactcag cgggttcac 23040
 accgtaatt cacttccgc ttcgctggg tcttctctt ccttctcgt ccgcatacca 23100
 cgcgccactg ggtcgtctt attcagccg cgcactgtg gcttacctc ttgcatgc 23160
 ttgattagca ccggtgggtt gctgaaccc accatttga gcgccatc ttctttct 23220
 tctcgtgtt ccagattac ctctggtgat ggcgggcgct cgggcttggg agaagggcg 23280

ttctttttct tcttgggctc aatggccaaa tccgccgccc aggtcgatgg ccgagggctg 23340
 ggtgtgcgcg gcaccagcgc gtcttgtgat gagtcttctt cgtctcggga ctcgatacgc 23400
 cgcctcatcc gcttttttgg gggcgcccgg ggaggcggcg gcgacgggga cggggacgac 23460
 acgtctcca tgggtggggg acgtcgccc gcaccgcgtc cgcgctcggg ggtggtttcg 23520
 cgtgctcct cttcccact ggccatttcc ttctctata ggcagaaaa gatcatggag 23580
 tcagtcgaga agaaggacag cctaaccgcc ccctctgagt tcgccaccac cgcctccacc 23640
 gatgcccca acgcgcctac cacttcccc gtcgaggcac ccccgttga ggaggaggaa 23700
 gtgattatcg agcaggaccc aggttttcta agcgaagacg acgaggaccg ctacgtacca 23760
 acagaggata aaaagcaaga ccaggacaac gcagaggcaa acgaggaaac agtcgggagg 23820
 ggggacgaaa ggcatggcga ctacctagat gtgggagacg acgtgctgtt gaagcatctg 23880
 cagcgccagt gcgccattat ctgcgacgcg ttgcaagagc gcagcgatgt gcccctcgcc 23940
 atagcggatg tcagccttgc ctacgaacgc cactatttct caccgcgctg acccccaaaa 24000
 cgccaagaaa acggcacatg cgagcccaac ccgcgcctca acttctaccc cgtatttggc 24060
 gtgccagagg tgcttgccac ctatcacatc tttttccaaa actgcaagat accctatcc 24120
 tgccgtgcca accgcagccc agcggaacag cagctggcct tgcggcaggg cgtgtcata 24180
 cctgatatcg cctcgctcaa cgaagtcca aaaatctttg agggcttgg acgcgacgag 24240
 aagcgcgccc caaacgctct gcaacaggaa aacagcgaaa atgaaagtca ctctggagtg 24300
 ttggtggaac tcgagggtga caacgcgcgc ctagccgtac taaaacgcag catcgaggtc 24360
 accactttg cctaccggc acttaacct cccccaagg tcatgagcac agtcatgagt 24420
 gagtcatgct tgcgccgtgc gcagcccctg gagaggatg caaatttga agaacaaca 24480
 gaggaggccc taccgcagt tggcgacgag cagctagcgc gctggcttca aacgcgcgag 24540
 cctgcccact tggaggagcg acgcaacta atgatggccg cagtgtcctg taccgtggag 24600
 ctgagtgta tcagcggtt ctgtgtgac ccggagatgc agcgaagct agaggaaaca 24660
 ttgactaca ctttgcga gggctacga cccaggcct gcaagatct caacgtggag 24720
 ctctgaacc tggctccta cttgggaatt ttgcagaaa accgccttgg gcaaaacgtg 24780
 cttcatcca cgtcaaggc cgaggcgcgc cgcgactacg tccgcgactg cgtttacta 24840
 ttctatgct acacctggca gacggccatg ggcttttggc agcagtgcct ggaggagtgc 24900
 aacctcaagg agctgcagaa actgctaag caaaactga aggacctatg gacggccttc 24960
 aacgagcgt cgtggccgc gcacctggcg gacatcattt tccccgaac cctgcttaa 25020
 accctgaac agggcttgc agacttacc agtcaaagca tgttcagaa cttaggaac 25080
 ttatcttag agcgtcagg aatcttccc gccacctgct gtgcacttcc tagcacttt 25140
 gtgcccatta agtaccgca atgcctccg ccgttttggg gccactgcta cttctgag 25200
 ctagccaact accttgcta ccacttgac ataattgaag acgtgagcgg tgacggtcta 25260
 ctggagtgc actgtcgtg caacctatgc accccgacc gctccctggt ttgaattcg 25320
 cagctgcta acgaaagtca aattatcgg acctttgagc tgcagggtcc ctgcctgac 25380
 gaaaagtccg cggctccggg gttgaaact actccggggc tgtggacgtc ggcttacct 25440
 cgcaaatgt tacctgagga ctaccagcc cagagatta ggttctacga agaccaatcc 25500
 cgcccgccta atgcggagct taccgcctgc gtcattaccc agggccacat tcttgccaa 25560
 ttgcaagcca tcaacaaagc ccgccaagag tttctgtac gaaaggagc gggggtttac 25620
 ttgatcccc agtccggcga ggagctaac ccaatcccc cgccgcccga gccctatcag 25680
 cagcagcccg gggcccttgc ttcccaggat ggcacccaaa aagaagctgc agctgccgc 25740
 gcccccacg gacgaggagg aatactggga cagtcaggca gaggagggtt tggacgagga 25800
 ggaggaggac atgatggaag actgggagag cctagacgag gaagcttccg aggtcgaaga 25860
 ggtgtcagac gaaacacct caccctcgg cgcattcccc tcgccggcg cccagaaatc 25920
 ggcaaccgt tcagcatgg ctacaacct cgtcctcag gcgccggcg cactgcccgt 25980
 tcgccagcc aaccgtagat gggacaccac tggaaaccag gccggtaagt ccaagcagcc 26040
 gccgccgta gcccaagagc aacaacagc ccaaggctac cgtcatggc gggggcaca 26100
 gaacgcata gttgcttct tgaagactg tgggggcaac atctcctcg cccgcgctt 26160
 tcttctac catcacggc tggccttccc ccgtaacat ctgcattact accgtcatct 26220
 ctacagcca tactgcaccg gcggcagcgg cagcaacagc agcgccaca cagaagcaa 26280

· ggcgaccgga tagcaagact ctgacaaagc ccaagaaatc cacagcggcg gcagcagcag 26340
 gaggaggagc gctgcgtctg gcgccaacg aaccgtatc gaccgcgag ctagaaca 26400
 ggattttcc cactctgtat gctatattc aacagagcag gggccaagaa caagagctga 26460
 aaataaaaa caggtctctg cgatccctca cccgcagctg cctgtatcac aaaagcgaag 26520
 atcagcttcg gcgcacgctg gaagacgcgg aggtctctt cagtaaatac tgcgcgctga 26580
 ctctaagga ctagtctgc gccctttctc aaatttaagc gcgaaaacta cgtcatctcc 26640
 agcggccaca cccggcgcca gcacctgttgc tcagcggcat tatgagcaag gaaattccca 26700
 cgccctacat gtggagttac cagccacaaa tgggacttgc ggctggagct gcccaagact 26760
 actcaaccg aataaactac atgagcgcgg gaccccat gatatcccg gtcaacggaa 26820
 tacgcgcca ccgaaccga attctctgg aacaggcggc tattaccac acacctcgt 26880
 ataacctaa tccccgtagt tggcccgctg ccctgggtga ccaggaaagt cccgctcca 26940
 ccactgtgtg acttccaga gacgccagg ccgaagtca gatgactaac tcagggcgcg 27000
 agcttgcggg cggtttctg cacagggtgc ggtcgcccg gcagggtata actcacctga 27060
 caatcagagg gcgaggtatt cagctcaacg acgagtcggg gagctcctc cttggctcc 27120
 gtccggacgg gacatttcag atcgccggcg cggcgccctc ttatttcacg cctcgtcagg 27180
 caatcctaac tctgcagacc tcgtcctcgc agccgcgctc tggaggcatt ggaactctgc 27240
 aattattga ggagttgtg ccatcggtct actttaacc cttctggga cctccggcc 27300
 actatccgga tcaattatt ctaactttg acgcggtaaa ggactcggcg gacggctacg 27360
 actgaatgt ataagttct gtccatccg acccactatc ttcatgtgt tgcagatgaa 27420
 gcgcgaaga ccgtcgaag atacctcaa ccccggtat ccatatgaca cggaaaccgg 27480
 tctccaact gtgcctttc ttactctcc cttgtatcc ccaatgggt tcaagagag 27540
 tccccggg gtactctct tgcgcctatc cgaacctta gttacctca atggcatgct 27600
 tgcgtcaaa atgggcaacg gccctctct ggacgaggcc ggcaacctta cttcccaaaa 27660
 tctaaccat gtgagccac cttcaaaaa aaccaagta aacataaacc tggaaatc 27720
 tgcacccctc acagttacct cagaagccct aactgtggct gcgcgcac cctaaggt 27780
 cgcgggcaac acactacca tgcaatcaca ggccccgta accgtgcacg actccaaact 27840
 tagcattgcc accaaggac cctcacagt gtcagaagga aagctagccc tgcaaacatc 27900
 agggccctc accaccacg atagcgtac ccttactatc actgctcac cccctcaac 27960
 tactgccact ggtagcttg gcattgactt gaaagagccc atttatacac aaaatggaaa 28020
 actaggacta aagtacggg ctccttgca tgtaacagac gacctaaaca cttgaccgt 28080
 agcaactggt ccaggtgtga ctattaataa tacttcttg caactaaag ttactggagc 28140
 ctgggtttt gattcacaag gcaatatgca actaatgta gcaggaggac taaggattga 28200
 ttctcaaac agacgccta tacttgatgt tagttatccg ttgatgctc aaaaccaact 28260
 aaatctaaga ctaggacagg gcccttttt tataaactca gcccaact tggatattaa 28320
 ctacaacaaa ggcctttact gtgttacgc ttcaacaat tcaaaaagc ttgaggtaa 28380
 cctaagcact gccagggggt tgatgttga cgctacagcc atagccatta atgcaggaga 28440
 tgggctgaa ttgggtcac ctaatgcacc aaacacaaat cccctcaaaa caaaaattg 28500
 ccatggccta gaatttgatt caacaaggc tatgggtcct aaactaggaa ctggccttag 28560
 tttgacagc acaggtgcca ttacagtagg aaacaaaaat aatgataagc taactttgtg 28620
 gaccaccca gctcatctc ctaactgtag actaaatgca gagaaagatg ctaaactcac 28680
 tttggtcta acaaatgtg gcagtcaaat acttgctaca gtttcagttt tggctgttaa 28740
 aggcagtttg gctccaatat ctggaacagt tcaaagtgt catctatta taagattga 28800
 cgaaaatgga gtgctactaa acaattcct cctggacca gaattattga actttagaaa 28860
 tggagatct actgaaggca cagcctatac aaacgctgtt ggatttatgc ctaacctatc 28920
 agcttatcca aaatctacg gtaaaactgc caaaagtaac attgtcagtc aagtttact 28980
 aaacggagac aaaactaac ctgtaact aaccattaca ctaaacggta cacaggaaac 29040
 aggagacaca actccaagt cactctat gtcattttca tgggactgg ctggccaca 29100
 ctacattaat gaaattttg ccactcctc ttactttt tcatacatg ccaagaata 29160
 aagaatcgt tgtgttatgt ttcaacgtgt ttattttca attgcagaaa atttcaagtc 29220
 attttcatt cagtagtata gccccaccac cacatagctt atacagatca ccgtacctta 29280

atcaaaactca cagaacccta gtattcaacc tgccacctcc ctccaacac acagagtaca 29340
 cagtcctttc tccccggctg gccttaaaaa gcatcatatc atgggtaaca gacataattc 29400
 taggtgttat attccacacg gtttctgtc gagccaaacg ctatcagtg atattaataa 29460
 actccccggg cagctcactt aagttcatgt cgctgtccag ctgtgagcc acaggctgct 29520
 gtccaacttg cgggtgctta acgggcgcg aaggagaagt ccacgcctac atgggggtag 29580
 agtcataatc gtgcatcagg ataggcggtt ggtgctgcag cagcgcgca ataaactgct 29640
 gccgccgccc ctccgtcctg caggaataca acatggcagt ggtctctca gcgatgattc 29700
 gcaccgccc cagcataagg cgccttgctc tccgggcaca gcagcgacc ctgatctcac 29760
 ttaaatcagc acagtaactg cagcacagca ccacaatatt gttcaaaatc ccacagtga 29820
 aggcgctgta tccaaagctc atggcgggga ccacagaacc cagtgggca tcataccaca 29880
 agcgaggta gattaagtgg cgacccctca taaacacgct ggacataaac attacctctt 29940
 ttggcatgtt gtaattcacc acctccggt accatataaa cctctgatta aacatggcgc 30000
 catccaccac catcctaaac cagctggcca aaacctgccc gccggctata cactgcaggg 30060
 aaccgggact ggaacaatga cagtggagag cccaggactc gtaacctgg atcatcatgc 30120
 tcgtcatgat atcaatgttg gcacaacaca ggacacgtg catacattc ctaggatta 30180
 caagctctc ccgctgtaga accatatccc agggacaac ccattcctga atcagcgtaa 30240
 atcccacact gcagggaaga cctgcacgt aactcacgtt gtgcattgtc aaagtgtac 30300
 attcgggcag cagcggatga tctccagta tggtagcgcg ggttctgtc tcaaaaggag 30360
 gtagacgac cctactgtac ggagtgcgc gagacaaccg agatcgtgtt ggtcgtagt 30420
 tcatgccaaa tggaaacgccc gacgtagtca tatttctga agcaaaacca ggtgcggg 30480
 tgacaacag atctgcgtc cgggtctgc cgcttagatc gctctgtgta gtagttgtag 30540
 tatatccact ctctcaaac atccaggcgc cccctggctt cgggttctat gtaaaactct 30600
 tcatgcgccc ctgcctgat aacatccacc accgcagaat aagccacacc cagccaacct 30660
 acacattcgt tctgcgagtc acacacggga ggagcgggaa gagctggaag aacctgttt 30720
 tttttttat tccaaaagat tatccaaaac ctcaaatga agatctatta agtgaacgcg 30780
 ctccctcgc gtagcgtgt caaactctac agocaaagaa cagataatgg cattgtgaag 30840
 atgttgaca atggcttca aaaggcaaac ggccctcagc tcaaagtga cgtaaaggct 30900
 aaaccttca gggtagaatc cctctataaa cattccagca ccttcaacca tgcccaata 30960
 attctatct cgcaccttc tcaatatatc tctaagcaaa tcccgaatat taagtccggc 31020
 cattgtaaaa atctgtcca gagcgccctc caccttcagc ctcaagcagc gaatcatgat 31080
 tgcaaaaatt caggttcctc acagacctgt ataagattca aaagcggaa attacaataa 31140
 ataccgcgat cccgtaggct ccttcgcagg gccagctgaa cataatcgtg caggtctgca 31200
 cggaccagcg cggccattc cccgccagga accatgaca aagaaccac actgattatg 31260
 acacgcatac tcggagctat gctaaccagc gtagccccga tgtaagcttg ttgcatggg 31320
 ggcatataa aatgcaagg gctgtctaaa aaatcaggca aagcctcgcg caaaaaagaa 31380
 agcacatcgt agtcatgctc atgcagataa aggcaggtaa gctccggaac caccacagaa 31440
 aaagacacca ttttctctc aaacatgtct gcgggttct gcataaacac aaaataaat 31500
 aacaaaaaa catttaaaac ttagaagcct gtcttaaac aggaataaac accctataa 31560
 gcataagacg gactacggcc atgccggcgt gaccgtaaaa aaactggta ccgtgattaa 31620
 aaagcaccac egacagctcc tcggtcatgt ccggagtc atgtgaagac tcggtaaaac 31680
 catcagggtt attcatatcg gtcagtgcct aaaagcgacc gaaatagccc gggggaatac 31740
 ataccgcag gcgtagagac aacattacag ccccatagg aggtataaca aaattaatag 31800
 gagagaaaaa cacataaac cctgaaaaac cctcctgcct aggcataata gcacctccc 31860
 gctccagaac aacatacagc gcttcacag cggcagccat aacagtcagc ctaccagta 31920
 aaaaaaagg gccaagtga gagcgagat atataggact aaaaaatgac gtaacggta 32040
 aagtccacaa aaaaaccca gaaaaccgca gcgaaccta cggcagaaa cgaagccaa 32100
 aaaaccaca acttctcaa atcgtcatt ccgtttccc acgttacgtc acttccatt 32160
 ttaagaaaaa tacaattccc aacataaca agttactccg ccataaacc tacgtaccc 32220
 gccccgttc cagccccgc gccacgtcac aaactccacc cctcattat catattggct 32280

tcaatccaaa ataaggata ttattgatga tgttacatcg ttaattaacg atttcgaacc 32340
 cgggggtaccg aatttcctcga gtctagagga gcatgacgacg tcgcaattcg ccctatagtg 32400
 agtcgtatta caattcactg gccgtcgtt tacaacgtcg tgactgggaa aaccttgccg 32460
 ttaccaact taatcgctt gcagcacatc cccctttcgc cagctggcgt aatagcgaag 32520
 agggccgcac cgatcgccct tccaacagt tgcgcagcct gaatggcgaa tggaaattgt 32580
 aagcgtaat atttgttaa aattcgcggt aaattttgt taaatcagct catttttaa 32640
 ccaataggcc gaaatcgga aaatccctta taaatcaaaa gaatagaccg agatagggtt 32700
 gagtgttgtt ccagtttga acaagagtcc actattaag aacgtggact ccaacgtcaa 32760
 agggcgaaaa accgtctatc agggcgatgg cccactacgt gaaccatcac cctaataag 32820
 tttttgggg tcgaggtgcc gtaagcact aaatcggaac ctaaaggga gccccgatt 32880
 tagagcttga cggggaagc cggcgaacgt ggcgagaaag gaagggaaga aagcgaaagg 32940
 agcggcgct agggcgctgg caagtgtagc ggtcacgctg cgcgtaacca ccacaccgc 33000
 cgcgctaat cgcgcgtac agggcgctc ctgatcggtt atttctct tacgcatcg 33060
 tgcggtattt cacaccgat acaggtggca ctttcgggg aaatgtgcgc ggaacccta 33120
 ttgtttatt ttctaata cattcaata tttatccgt catgagaca taacctgat 33180
 aaatgcttca ataattga aaaaggaga gtatgagtat tcaacattc cgtgtcgccc 33240
 ttattccctt ttttcggga ttttccttc ctgttttgc tcaccagaa acgttggtga 33300
 aagtaaaaga tgctgaagat cagttgggtg cagcagtggt ttacatcga ctggatctca 33360
 acagcgtaa gatccttgag agttttcgcc cgaagaacg tttccaatg atgagcactt 33420
 ttaaagtct gctatgtggc gcggtattt cccgtattga cggcgggcaa gagcaactcg 33480
 gtcgcgcgt acactattt cagaatgact tggttgagta ctcaccagtc acagaaaagc 33540
 atcttacgga tggcatgaca gtaagagaat tatgcagtgc tgccataacc atgagtata 33600
 aacttcggc caacttact ctgacaacga tcggaggacc gaaggagcta accgctttt 33660
 tgcacaacat gggggatcat gtaactcgc ttgatcgtt ggaaccggag ctgaatgaag 33720
 ccataccaaa cgacgagcgt gacaccaga tgctgtagc aatggcaaca acgttgcga 33780
 aactattaac tggcgaacta ctactctag ctcccgga acaattaata gactggatgg 33840
 aggcggataa agttgcagga ccactctgc gtcggccct tcggctggc tggttattg 33900
 ctgataaatc tggagccggt gagcgtgggt ctgcggtat cattgcaga ctggggccag 33960
 atggtaagcc ctccgtatc gtagttatc acacgacggg gtagcaggca actatggatg 34020
 aacgaaatag acagatcgt gagatagggt cctcactgat taagcattgg taactgtcag 34080
 accaagtta ctatatata cttagattg atttaaaact tcattttta tttaaaagga 34140
 tctagtgaa gatcctttt gataatctca tgacaaaat ccctaacgt gagtttcgt 34200
 tccactgagc gtcagacccc gtagaaaaga tcaaggatc ttcttgat cttttttc 34260
 tgcgcgtaat ctgctgctt caaacaataa aaccaccgt accagcgggt gttgtttgc 34320
 cggatcaaga gctaccaact cttttccga aggtaactgg ctcagcaga gcgcagatac 34380
 caaatactgt tcttctagtg tagccgtagt taggccacca ctcaagaac tctgtagcac 34440
 cgctacata cctcgctctg ctaatcctgt taccagtggc tgctgccagt ggcgataagt 34500
 cgtgtcttac cgggttggac tcaagcgtat agttaccgga taaggcgag cggtcgggt 34560
 gaacgggggg ttcgtgcaca cagccagct tggagcgaac gacctacac gaactgagat 34620
 acctacagcg tgagctatga gaaagcgcca cgctcccgaggaggagaaag gcggacaggt 34680
 atccggttaag cggcagggtc ggaacaggag agcgacagag ggagcttcca gggggaaagc 34740
 cctggtatct ttatgtct gtcgggttt gccacctctg acttgagcgt cgattttgt 34800
 gatgctctg agggggggcgg agcctatgga aaaacggcag caacgcggcc ttttacggt 34860
 tctggcctt ttgctggcct ttgtctaca tgtttttcc tgcgttatcc cctgattctg 34920
 tggataaccg tattaccgcc ttgagttag ctgataccg tcgccgacg cgaacgaccg 34980
 agcgacgca gtcagttagc gaggaagcgg aagagcgccc aatacgaaa ccgctctcc 35040
 ccgctgttg gccgattcat taatgcagct ggcacgacag gtttccgac tggaaagcgg 35100
 gcagttagcg caacgcaatt aatgtgagtt agctcactca ttaggcaccc caggctttac 35160
 actttatgct tccggctcgt atgtgtgtg gaattgtgag cggataaca tttcacacag 35220
 gaaacagcta tgacatgat tacgcaagc tattaggtg acactataga atactcaagc 35280

tagttaatta acgttaatta acatcatcaa taatatacct tattttggat tgaagccaat 35340
atgataatga ggggggtggag tttgtgacgt ggcgcggggc gtgggaacgg ggcgggtgac 35400
gtagtagtgt ggcggaagtg tgatgttgca agtgtggcgg aacacatgta agcgacggat 35460
gtggcaaaag tgacgttttt ggtgtgcgcc ggtgtacaca ggaagtgaca attttcgcgc 35520
ggtttttaggc ggatgttgta gtaaatttgg gcgtaaccga gtaagatttg gccattttcg 35580
cgggaaaact gaataagagg aagtgaaatc tgaataattt tgtgttactc atagcgcgta 35640
atctctagca t 35651

<212> Type : DNA

<211> Length : 35651

SequenceName : SEQ ID No.1

SequenceDescription :

Custom Codon

• Sequence Name : SEQ ID No.1

REFERENCES

1. **Andersen, M. M. and T. Ronne.** 1991. Side-effects with Japanese encephalitis vaccine. *Lancet* **337**:1044.
2. **Ashok, M. S. and P. N. Rangarajan.** 2000. Immunization with plasmid DNA encoding the envelope glycoprotein of Japanese encephalitis virus confers significant protection against intracerebral viral challenge without inducing detectable antiviral antibodies. *Vaccine* **18**:68-75.
3. **Both, G. W., L. J. Lockett, V. Janardhana, S. J. Edwards, A. R. Bellamy, F. L. Graham, L. Prevec, and M. E. Andrew.** 1993. Protective immunity to rotavirus-induced diarrhoea is passively transferred to newborn mice from naive dams vaccinated with a single dose of a recombinant adenovirus expressing rotavirus VP7sc. *Virology* **193**:940-950.
4. **Casimiro, D. R., A. Tang, L. Chen, T. M. Fu, R. K. Evans, M. E. Davies, D. C. Freed, W. Hurni, J. M. Aste-Amezaga, L. Guan, R. Long, L. Huang, V. Harris, D. K. Nawrocki, H. Mach, R. D. Troutman, L. A. Isopi, K. K. Murthy, K. Rice, K. A. Wilson, D. B. Volkin, E. A. Emini, and J. W. Shiver.** 2003. Vaccine-induced immunity in baboons by using DNA and replication-incompetent adenovirus type 5 vectors expressing a human immunodeficiency virus type 1 gag gene. *J Virol.* **77**:7663-7668.
5. **Chambers, T. J., C. S. Hahn, R. Galler, and C. M. Rice.** 1990. Flavivirus genome organization, expression and replication. *Annu. Rev. Microbiol.* **44**:649.
6. **Chang, G.-J. J., A. R. Hunt, and B. Davis.** 2000. A single intramuscular injection of recombinant plasmid DNA induces protective immunity and prevents Japanese encephalitis in mice. *Journal of Virology* **74**:4244-4252.
7. **Chen, H. W., C. H. Pan, M. Y. Liau, R. Jou, C. J. Tsai, H. J. Wu, Y. L. Lin, and M. H. Tao.** 1999. Screening of protective antigens of Japanese encephalitis virus by DNA immunization: a comparative study with conventional viral vaccines. *J. Virol.* **73**:10137-10145.
8. **Chengalvala, M. V., B. M. Bhat, R. A. Bhat, S. K. Dheer, M. D. Lubeck, R. H. Purcell, and K. K. Murthy.** 1997. Replication and immunogenicity of Ad7-,

- Ad4-, and Ad5-hepatitis B virus surface antigen recombinants, with or without a portion of E3 region, in chimpanzees. *Vaccine* **15**:335-339.
9. **Flanagan, B., C. R. Pringle, and K. N. Leppard.** 1997. A recombinant human adenovirus expressing the simian immunodeficiency virus Gag antigen can induce long-lived immune responses in mice. *J Gen. Virol.* **78 (Pt 5)**:991-997.
10. **Fonseca, B. A., S. Pincus, R. E. Shope, E. Paoletti, and P. W. Mason.** 1994. Recombinant vaccinia viruses co-expressing dengue-1 glycoproteins prM and E induce neutralizing antibodies in mice. *Vaccine* **12**:279-285.
11. **Fooks, A. R., D. Jeevarajah, J. Lee, A. Warnes, S. Niewiesk, M. ter, V, J. R. Stephenson, and J. C. Clegg.** 1998. Oral or parenteral administration of replication-deficient adenoviruses expressing the measles virus haemagglutinin and fusion proteins: protective immune responses in rodents. *J Gen. Virol.* **79 (Pt 5)**:1027-1031.
12. **Guirakhoo, F., R. Weltzin, T. J. Chambers, Z. X. Zhang, K. Soike, M. Ratterree, J. Arroyo, K. Georgakopoulos, J. Catalan, and T. P. Monath.** 2000. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates. *J Virol.* **74**:5477-5485.
13. **Imler J.L.** 1995. Adenovirus vectors as recombinant viral vaccines. *Vaccine* **13**:1143-1151.
14. **Jan, L. R., C. S. Yang, L. S. Henchal, H. Sumiyoshi, P. L. Summers, D. R. Dubois, and C. J. Lai.** 1993. Increased immunogenicity and protective efficacy in outbred and inbred mice by strategic carboxyl-terminal truncation of Japanese encephalitis virus envelope glycoprotein. *Am. J Trop. Med. Hyg.* **48**:412-423.
15. **Kaur, R., G. Sachdeva, and S. Vрати.** 2002. Plasmid DNA immunization against Japanese Encephalitis Virus: immunogenicity of membrane-anchored and secretory envelope protein. *J. Infect. Dis.* **185**:1-12.
16. **Kaur, R. and S. Vрати.** 2003. Development of a recombinant vaccine against Japanese encephalitis. *J Neurovirol* **9**:421-431.
17. **Kimura-Kiroda, J. and K. Yasui.** 1988. Protection of mice against Japanese encephalitis virus by passive administration of monoclonal antibodies. *J. Immunol.* **141**:3606-3610.
18. **Konishi, E., S. Pincus, E. Paoletti, R. E. Shope, T. Burrage, and P. W. Mason.** 1992. Mice immunized with a subviral particle containing the Japanese

encephalitis virus prM/M and E proteins are protected from lethal JEV infection. *Virology* **188**:714-720.

19. **Konishi, E., M. Yamaoka, S. W. Khin, I. Kurane, K. Takada, and P. W. Mason.** 1999. The anamnestic neutralizing antibody response is critical for protection of mice from challenge following vaccination with a plasmid encoding the Japanese encephalitis virus premembrane and envelope genes. *J. Virol.* **73**:5527-5534.
20. **Konishi, E., M. Yamaoka, Khin-Sane-Win, I. Kurane, and Mason P.W.** 1998. Induction of protective immunity against Japanese encephalitis in mice by immunization with a plasmid encoding Japanese encephalitis virus premembrane and envelope genes. *Journal of Virology* **72**:4925-4930.
21. **Lemiale, F., W. P. Kong, L. M. Akyurek, X. Ling, Y. Huang, B. K. Chakrabarti, M. Eckhaus, and G. J. Nabel.** 2003. Enhanced mucosal immunoglobulin A response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system. *J Virol.* **77**:10078-10087.
22. **Lin, B., C. R. Parrish, J. M. Murray, and P. J. Wright.** 1994. Localization of a neutralizing epitope on the envelope protein of dengue virus type 2. *Virology* **202**:885-890.
23. **Livingston, P. G., I. Kurane, C. J. Lai, M. Bray, and F. A. Ennis.** 1994. Recognition of envelope protein by dengue virus serotype-specific human CD4+ CD8- cytotoxic T-cell clones. *J Virol.* **68**:3283-3288.
24. **Lubeck, M. D., A. R. Davis, M. Chengalvala, R. J. Natuk, J. E. Morin, K. Molnar-Kimber, B. B. Mason, B. M. Bhat, S. Mizutani, P. P. Hung, and .** 1989. Immunogenicity and efficacy testing in chimpanzees of an oral hepatitis B vaccine based on live recombinant adenovirus. *Proc. Natl. Acad. Sci. U. S. A* **86**:6763-6767.
25. **Mason P.W., S. Pincus, M. J. Fournier, T. L. Mason, R. E. Shope, and E. Paoletti.** 1991. Japanese encephalitis virus-Vaccinia recombinants produce particulate forms of the structural membrane proteins and induce high levels of protection against lethal JEV infection. *Virology* **180**:294-305.
26. **McMinn, P. C.** 1997. The molecular basis of virulence of the encephalitogenic flaviviruses. *J Gen. Virol.* **78 (Pt 11)**:2711-2722.

27. **Men, R., M. Bray, and C.-J. Lai.** 1991. Carboxy-terminal truncated dengue virus envelope glycoprotein expressed on the cell surface and secreted intracellularly exhibit increased immunogenicity in mice. *Journal of Virology* **65**:1400-1407.
- 5 28. **Monath, T. P.** 2001. Prospects for development of a vaccine against the West Nile virus. *Ann. N. Y. Acad. Sci.* **951**:1-12.
29. **Monath, T. P.** 2002. Japanese encephalitis vaccines: current vaccines and future prospects. *Curr. Top. Microbiol. Immunol.* **267**:105-138.
- 10 30. **Monath, T. P., K. McCarthy, P. Bedford, C. T. Johnson, R. Nichols, S. Yoksan, R. Marchesani, M. Knauber, K. H. Wells, J. Arroyo, and F. Guirakhoo.** 2002. Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections. *Vaccine* **20**:1004-1018.
- 15 31. **Monath, T. P., K. Soike, I. Levenbook, Z. X. Zhang, J. Arroyo, S. Delagrave, G. Myers, A. D. Barrett, R. E. Shope, M. Ratterree, T. J. Chambers, and F. Guirakhoo.** 1999. Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates. *Vaccine* **17**:1869-1882.
- 20 32. **Pan, C. H., H. W. Chen, H. W. Huang, and M. H. Tao.** 2001. Protective mechanisms induced by a Japanese encephalitis virus DNA vaccine: requirement for antibody but not CD8(+) cytotoxic T-cell responses. *J Virol.* **75**:11457-11463.
33. **Plesner, A. M. and T. Ronne.** 1997. Allergic mucocutaneous reactions to Japanese encephalitis vaccine. *Vaccine* **15**:1239-1243.
- 25 34. **Putnak, R., R. Feighny, J. Burrous, M. Cochran, C. Hackett, G. Smith, and C. Hoke.** 1991. Dengue-1 virus envelope glycoprotein gene expressed in recombinant baculovirus elicits virus-neutralizing antibody in mice and protects them from virus challenge. *Am. J Trop. Med. Hyg.* **45**:159-167.
- 30 35. **Raikwar, S. P., P. Malik, O. Singh, and S. Vрати.** 1997. Recombinant adenovirus synthesizing cell surface-anchored beta hCG induces bionutralizing antibodies in rats. *Gene* **190**:197-202.
36. **Ramakrishna, C., A. Desai, S. K. Shankar, A. Chandramuki, and V. Ravi.** 1999. Oral immunisation of mice with live Japanese encephalitis virus induces a protective immune response. *Vaccine* **17**:3102-3108.

37. **Raviprakash, K., T. J. Kochel, D. Ewing, M. Simmons, I. Phillips, C. G. Hayes, and K. R. Porter.** 2000. Immunogenicity of dengue virus type 1 DNA vaccines expressing truncated and full length envelope protein. *Vaccine* **18**:2426-2434.
- 5 38. **Ruff, T. A., D. Eisen, A. Fuller, and R. Kas.** 1991. Adverse reactions to Japanese encephalitis vaccine. *Lancet* **338**:881-882.
39. **Sakaguchi, M., M. Yoshida, W. Kuroda, O. Harayama, Y. Matsunaga, and S. Inouye.** 2000. Systemic immediate-type reactions to gelatin included in Japanese encephalitis vaccines. *Vaccine* **15**:121-122.
- 10 40. **Sharpe, S., A. Fooks, J. Lee, K. Hayes, C. Clegg, and M. Cranage.** 2002. Single oral immunization with replication deficient recombinant adenovirus elicits long-lived transgene-specific cellular and humoral immune responses. *Virology* **293**:210-216.
41. **Shiver, J. W., T. M. Fu, L. Chen, D. R. Casimiro, M. E. Davies, R. K. Evans, Z. Q. Zhang, A. J. Simon, W. L. Trigona, S. A. Dubey, L. Huang, V. A. Harris, R. S. Long, X. Liang, L. Handt, W. A. Schleif, L. Zhu, D. C. Freed, N. V. Persaud, L. Guan, K. S. Punt, A. Tang, M. Chen, K. A. Wilson, K. B. Collins, G. J. Heidecker, V. R. Fernandez, H. C. Perry, J. G. Joyce, K. M. Grimm, J. C. Cook, P. M. Keller, D. S. Kresock, H. Mach, R. D. Troutman, L. A. Isopi, D. M. Williams, Z. Xu, K. E. Bohannon, D. B. Volkin, D. C. Montefiori, A. Miura, G. R. Krivulka, M. A. Lifton, M. J. Kuroda, J. E. Schmitz, N. L. Letvin, M. J. Caulfield, A. J. Bett, R. Youil, D. C. Kaslow, and E. A. Emini.** 2002. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. *Nature* **415**:331-335.
- 15 20 25 42. **Vos, A., A. Neubert, E. Pommerening, T. Muller, L. Dohner, L. Neubert, and K. Hughes.** 2001. Immunogenicity of an E1-deleted recombinant human adenovirus against rabies by different routes of administration. *J Gen. Virol.* **82**:2191-2197.
43. **Vrati, S., V. Agarwal, P. Malik, S. A. Wani, and M. Saini.** 1999. Molecular characterization of an Indian isolate of Japanese encephalitis virus that shows an extended lag phase during growth. *J. Gen. Virol.* **80**:1665-1671.
- 30

44. **Vrati, S., R. K. Giri, A. Razdan, and P. Malik.** 1999. Complete nucleotide sequence of an Indian strain of Japanese encephalitis virus: sequence comparison with other strains and phylogenetic analysis. *Am. J. Trop. Med. Hyg.* **61**:677-680.
45. **World Health Organization.** 1998. Japanese encephalitis vaccines. *Wkly Epidemiol Rec* **73**:334-344.
46. **Xiang, Z., Y. Li, G. Gao, J. M. Wilson, and H. C. Ertl.** 2003. Mucosally delivered E1-deleted adenoviral vaccine carriers induce transgene product-specific antibody responses in neonatal mice. *J Immunol.* **171**:4287-4293.
47. **Xiang, Z. Q., G. P. Gao, A. Reyes-Sandoval, Y. Li, J. M. Wilson, and H. C. Ertl.** 2003. Oral vaccination of mice with adenoviral vectors is not impaired by preexisting immunity to the vaccine carrier. *J Virol.* **77**:10780-10789.
48. **Xiang, Z. Q., Y. Yang, J. M. Wilson, and H. C. Ertl.** 1996. A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier. *Virology* **219**:220-227.
49. **Yoshida, T., K. Okuda, K. Q. Xin, K. Tadokoro, J. Fukushima, S. Toda, E. Hagiwara, K. Hamajima, T. Koshino, and T. Saito.** 2001. Activation of HIV-1-specific immune responses to an HIV-1 vaccine constructed from a replication-defective adenovirus vector using various combinations of immunization protocols. *Clin. Exp. Immunol.* **124**:445-452.
50. **Zhao, J., Y. Lou, J. Pinczewski, N. Malkevitch, K. Aldrich, V. S. Kalyanaraman, D. Venzon, B. Peng, L. J. Patterson, Y. Edghill-Smith, R. Woodward, G. N. Pavlakis, and M. Robert-Guroff.** 2003. Boosting of SIV-specific immune responses in rhesus macaques by repeated administration of Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinants. *Vaccine* **21**:4022-4035.